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ABSTRACT 
 
 
 
Brain Derived Neurotrophic Factor (BDNF), a member of the family of neurotrophins, is 
a key molecule involved in growth, development and modulation of neuronal system. 
Due to its critical role in a large number of neuronal processes including synaptic 
plasticity, BDNF altered function and levels are associated even more strongly with 
many different neuropsychiatric disorders such as schizophrenia and the associated 
cognitive impairment.  
In this PhD thesis, we demonstrated that BDNF, which mRNA is transported into 
dendrites in response to neuronal activity, is capable to be translated directly in the 
dendritic compartment after electrical stimulation. Considering that local protein 
synthesis (LPS) in dendrites is commonly accepted as a mechanism strongly involved in 
synaptic plasticity and cognitive processes, we designed a cellular assay based on the 
detection of BDNF LPS, for the identification of developing compounds able to improve 
cognitive performances in patients affected by neuropsychiatric disorders. 
In addition, we studied BDNF protein levels in serum of schizophrenic subjects, finding 
an alteration of the ratio between BDNF and its precursor form (proBDNF), known to 
elicits biological effects opposite to mature BDNF on neuronal system. Based on this 
evidence, we developed an ELISA kit for the measurement of proBDNF/BDNF ratio 
that could represent a powerful tool for diagnosis of psychosis and for the follow-up of 
the medical treatment.  
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PREFAX 
 
 
Although human interest in the nature of the mind sure goes back to long time ago, the 
systematic scientific search for the causes of mental disorders did not begin until the 
latest part of the 19th century. Even if from different perspectives, pionieristic works of 
renowned scientists like Emil Kraepelin, Sigmund Freud or Adolph Meyer began to shed 
light on previously not understood aspects of the human brain, including mental 
illnesses. During the following years, an increasing number of neurologists and 
psychologists focused their attention on psychosis, providing a deeper knowledge of the 
mechanisms involved in the disorders.  
In parallel with the scientific findings, incidence and prevalence of these mental disturbs 
have rapidly grown, probably due to the even more stressful 20th century lifestyle and 
other environmental factors. Today, neuropsychiatric disorders represent the second 
largest cause of morbidity and premature mortality worldwide. The World Health 
Organization has estimated that, collectively, neuropsychiatric disorders comprise 13% 
of all reported diseases, having a terrific impact on life quality of the patients affected. 
These disorders include major depression, anxiety, schizophrenia, bipolar disorder, 
obsessive-compulsive disorder, alcohol and substance abuse, and attention-deficit 
hyperactivity disorder and account for 50% of the disability in less developed and 
developing countries. Statistics can become even more alarming, considering that 
approximately one in five of worldwide population will experience an episode of a 
psychiatric illness such as schizophrenia, a mood disorder (depression and bipolar 
disorder) or anxiety along his life. The prevalence of these disorders, and their personal 
and social costs, has fuelled a half century of research aimed at elucidating the etiologies 
and pathophysiological mechanisms of these devastating disorders with the ultimate goal 
of designing pharmacotherapies that can correct the underlying neurochemical defects. 
However, despite of the outstanding efforts employed, many drugs in use today for 
treating neuropsychiatric disorders are at best refinements of compounds identified over 
40 years ago and found to be effective by empirical observations. As the biochemical 
mechanisms of action of the effective agents were elucidated, theories were postulated 
concerning the neurochemical bases for the disorders. Thus, in the 1960s, the dopamine 
hypothesis of schizophrenia and the monoamine theory of depression were introduced, 
based in large part upon the abilities of antischizophrenic drugs to block dopamine 
receptors and antidepressant drugs to increase synaptic levels of monoamine 
neurotransmitters. These concepts have continued to address drug development efforts 
until today. Recent results, particularly the identification of gene polymorphisms 
influencing a multitude of biochemical pathways, have revealed a molecular complexity 
of these disorders that was unappreciated until the past decade. It is increasingly clear 
that neuropsychiatric disorders arise from interactions of multiple predisposing genes of 
variable penetrance overlaid by diverse experiential and environmental influences. 
Elucidating the role of these genes in the pathogenesis and in the pathophysiology of 
psychosis could lead to an outstanding step forward in the diagnosis and the treatment of 
these disorders, including some common core features as cognitive impairment. 
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1. INTRODUCTION 
 
1.1 Neuropsychiatric disorders 
Neuropsychiatric disorders are a broad range of psychosis that include depression, 
bipolar disorders, anxiety, obsessive-compulsive disorder, attention deficit hyperactivity 
disorder, alcohol and drugs abuse, schizophrenia and other alterated mental conditions. 
To introduce these disorders, sharing some common aspects but also many peculiar 
features, it is important to underline their vast diffusion and to briefly summarize their 
characteristics. Thus, considering the incidence, the prevalence, the social costs and the 
amount of scientific information, it is possible to individuate four principal psychoses: 
  
Depression: 
Major depressive disorder (MDD) is a serious disorder that affects approximately 17% 
of the population at some point in life, resulting in major social and economic 
consequences (Hirschfeld 2002). According to the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV), MDD is a heterogeneous disorder that manifests with 
symptoms at the psychological, behavioural and physiological levels. There is still very 
little known about the neurobiological alterations that underlie the pathophysiology or 
treatment of MDD. Several lines of evidence suggest that depression in most people is 
caused by interactions between a genetic predisposition and some environmental factors 
(Costello et al. 2002; Merikangas et al. 2002; Nestler et al. 2002; Nestler et al. 2002). 
 
Bipolar disorder: 
Bipolar disorder (BD), also known as manic-depressive illness, is a brain disorder that 
causes unusual shifts in a person’s mood, energy, and ability to function. More than 2 
million American adults, or about 1% of the population age 18 and older in any given 
year, have BD (Spearing 2001). BD typically develops in late adolescence or early 
adulthood. However, some people have their first symptoms during childhood, and some 
develop them later in life. BD is often not recognized as an illness, and people may 
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suffer for years before it is properly diagnosed and treated. Like diabetes or heart 
disease, BD is a long-term illness that must be carefully managed throughout a person’s 
lifetime. 
 
Attention deficit hyperactivity disorder (ADHD): 
Attention deficit hyperactivity disorder (ADHD) is a behavioural diagnosis based on the 
presence of developmentally inappropriate levels of impulsivity, overactivity and 
inattentiveness. The overall prevalence for ADHD among children is estimated at around 
3–10% (Burd et al. 2003; Faraone et al. 2003; Ford et al. 2003), depending on the 
measure used and the population sampled. Boys are five times more often affected than 
girls (Ford et al. 2003). The disorder persists into adult life in around two-thirds of cases, 
either as the full condition or persistence of some symptoms associated with 
impairments in psychosocial functioning (Faraone et al. 2004; Asherson 2005). 
 
Schizophrenia: 
Schizophrenia is a chronic and debilitating mental illness characterized by loss of 
contact with reality (psychosis). It affects 1% of the world's population, or around 50 
million people, across all countries and socio-economic classes. The incidence of 
schizophrenia is concentrated in the 15–24 age group for both sexes, whilst the incidence 
rate for males in this age group is 0.06% compared to 0.04% for the female population. 
After the age of 25, the incidence of schizophrenia drops rapidly for both sexes, 
remaining relatively constant at 0.005% in those over the age of 45. The US has by far 
the largest prevalent schizophrenic population, consisiting of nearly 3.5 million patients. 
The aetiology of schizophrenia is complex, with both genetic and environmental 
components and the molecular basis of the disorder is still poorly understood. Familial 
studies have shown that the risk of developing schizophrenia is greater in parents, 
children and siblings of patients with the disorder than in the general population with the 
risk being highest in the monozygotic twin of an affected individual (Murphy et al. 
1996). A genetic basis for schizophrenia, however, cannot be inferred from the increased 
incidence in families as not all conditions that run in families are genetic. Recent studies 
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using magnetic resonance imaging (MRI) techniques have revealed anatomical 
abnormalities in some schizophrenic brains, a reduction in the volume of the thalamus, 
amygdala, hippocampus and an increase in ventricle size (Andreasen et al. 1994; Nelson 
et al. 1998). It is thought that these structural changes result from the combined actions 
of genes with other environmental factors such as a viral infection or perinatal injury. 
There is currently no simple laboratory test to make a diagnosis of schizophrenia which 
is based on symptomatic evaluation of the patient using certain tests to help rule out 
general medical conditions which could cause psychotic symptoms. However, the 
diagnosis of schizophrenia can be extremely difficult, with many patients going 
unrecognized for years. The symptoms necessary for definitive diagnosis may go 
unnoticed, or do not show themselves fully until the illness is advanced. Many 
physicians, well aware of the stigma that still surrounds schizophrenia, do not like to 
make a definitive diagnosis until they are sure that it is the correct one, with many 
adopting a 'watchful waiting' approach. In addition, up to 10% of the schizophrenic 
population may never make themselves eligible for diagnosis and this group of 
schizophrenics includes those patients whose symptoms never become sufficiently 
serious to warrant a visit to the physician, pre-diagnosis suicides and the schizophrenic 
homeless population. 
Symptoms of schizophrenia include: 
 
• positive symptoms, such as delusions (false beliefs based on incorrect 
perception of reality), hallucinations (sensory perceptions that occur in the 
absence of external stimuli), and disorganized speech or behaviour. 
•  negative (or deficit) symptoms such as affective flattening, alogia and 
avolition.  
 
Pharmacological treatment of schizophrenia could be divided in two main classes of 
compounds called typical and atypical antipsychotics drugs. Typical antipsychotics, 
although having effects on the positive symptoms of schizophrenia, also cause unwanted 
side effects including extra pyramidal symptoms. This class of compounds has a high 
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affinity for D2 receptors. Atypical antipsychotics, principally targeting a wider range of 
receptors, are generally more effective against the negative symptoms of schizophrenia, 
with less effects on extra pyramidal symptoms.  However, many atypical antipsychotics 
also cause unwanted side effects including elevations in prolactin and weight gain. 
In addition, a core component of the disorder is cognitive deficit, a peculiarity shared 
with almost all neuropsychiatric disorders. Schizophrenia patients have been 
demonstrated to show impairments in cognitive performances (Keefe et al. 2005), 
leading to a significant aggravation of life conditions and quality. Despite this and the 
large number of studies addressing cognition, this aspect of the disorder remains the 
most difficult to treat. 
 
 
1.2 The cognitive processes 
Defining cognitive processes is not so easy, not only because of the high complexity of 
the phenomenon and its poor comprehension, but also because it depends on the 
discipline that is trying to describe it. From a psychological point of view, the term 
cognition can be referred to abstract concepts such as mind, reasoning, perception, 
intelligence, learning, and many others that are related to numerous capabilities of the 
human brain. Consequently, this description tends to apply to processes such as memory, 
attention, perception, action, problem solving and mental imagery. However, cognitive 
processes is the objects of numerous studies in various other fields as for instance 
neurology, neuroscience, philosophy, systemics and in more recent years molecular and 
cellular cognition, a new scientific branch that integrate molecular, cellular, and 
behavioral mechanisms, trying to find common aspects and treatments for cognitive 
disorders.  
Even if an exhaustive cellular and molecular explanation of cognitive process is far to be 
reached, it is possible to identify synaptic plasticity, the ability of the brain to change the 
strength of synaptic connections in response to different stimuli, as a common 
mechanism to several mental faculties.  
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Based on very early experimental evidence that leaded Donald Hebb in 1949 (Hebb 
1949) to postulate its famous theory (“cells that fire together, wire together”), a huge 
number of studies tried to describe synaptic remodelling and its relathionship with 
cognition. It is now generally accepted that synaptic plasticity is the mechanism that 
underlies learning and memory formation. To study the molecular and cellular bases of 
these processes, scientific research identified some cellular models of synaptic plasticity, 
whose the best suited seems to be Long Term Potentiation or LTP. 
 
Cellular mechanisms of cognitive processes: Long Term Potentiation 
Firstly described as a synaptic potentiation of greater magnitude and persistence due to a 
repeated delivery of conditioning stimuli in the DG of the hippocampus (Bliss et al. 
1993), Long Term Potentiation (or its opposite equivalent Long Term Depression) has 
rapidly arisen as a fundamental tool to investigate the common aspects of mental 
processes.  
Experimentally, LTP can be induced in a variety of ways; however, the most widespread 
method is high-frequency (tetanic) and/or patterned electrical stimulation of afferent 
fibers. Depending on the receptors implicated, it can be distinct in two different forms: 
NMDA receptor-dependent (CA3–CA1 synapses in the hippocampus) (Palmer et al. 
2004) and NMDA receptor-independent (DG–CA3 mossy fiber synapses) (Nicoll et al. 
2005). Following the induction, from a temporal and functional point of view, it is 
possible to divide LTP in three different phases (Abraham 1991), as schematically 
represented in figure 1: 
 
 
• LTP1 or Early-LTP: depending on post-translational modification of existing 
proteins. 
• LTP2 or intermediate Late-LTP: depending on new protein synthesis. 
• LTP3 or Late-LTP: depending on new gene transcription and new protein 
synthesis. 
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Several studies have demonstrated that the switch from the early to the late phase of LTP 
and its maintenance requires de novo protein synthesis. Indeed, blocking protein 
synthesis in hippocampal CA1 region (Frey et al. 1988), in Mossy-fiber CA3 synapses 
(Huang et al. 1994), 1994) or in C-fiber evoked field potentials in spinal dorsal horn (Hu 
et al. 2003) results in a inhibition of late phase-LTP. 
 
 
 
 
 
Figure 1. Early and Late-phase LTP. The early phase (LTP1) involves post-translational 
modification of existing proteins, the intermediate phase (LTP2) depends on new protein 
synthesis, while the late phase (LTP3) requires not only new protein synthesis but also specific 
gene transcription. Each phase is regulated by intracellular calcium (Raymond 2007).  
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Once switched from the early to the late phase, LTP is also depending upon new gene 
transcription for its maintenance. A miscellany of Immediate-Early Genes (IEGs) 
encoding transcription factor and non-transcription factor proteins are induced following 
LTP induction (Williams et al. 1995; Tsui et al. 1996; Lanahan et al. 1997; Bozon et al. 
2003; Steward et al. 2007). Transcription factor IEGs such as zif268 (a.k.a. egr-1, ngfi-a, 
krox24) and nurr1 regulate late response genes, although the targets of these genes have 
yet to be identified. The non-transcription factor genes encode synaptic proteins such as 
activity-regulated cytoskeleton-associated protein (Arc; a.k.a. activity-regulated gene, 
Arg3.1) and Homer1a, as well as secreted proteins such as tissue plasminogen activator 
and neuronal activity-regulated pentraxin. However, LTP maintenance needs not only 
new gene transcription but also new protein synthesis.  
Once established the importance of new protein synthesis in a cellular analogue of 
learning and memory as LTP, it remains to be clarified how nervous system could assure 
spatial and temporal specificity of protein synthesis only to activated synapses. At 
present, three models are believed to be the most suited to explain the phenomenon 
(Jiang et al. 2002). The first one proposes a specific targeting of new synthesized 
proteins from the cell nucleus to activated synapses, the second one suggests a specific 
marking of activated synapses in order to deliver new synthesized proteins to them (or a 
specific capture ability), and finally the third one indicates local protein synthesis in 
dendrites as the responsible for specificity (see figure 2).  
Although the first two models might play a secondary role as well, a wide number of 
scientific evidence demonstrates that local protein synthesis is the central mechanism 
used by neurons to solve the problem. 
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Figure 2. The three models proposed for synaptic activity-induced protein synthesis in 
postsynaptic neurons (Jiang et al. 2002). 
 
 
Molecular mechanisms of cognitive processes: local protein synthesis in dendrites 
 
The discovery of polyribosomes in neuronal dendrites, and the preferential localization 
of them at the bases of dendritic spines (Steward et al. 1982), firstly suggested the idea 
of local protein synthesis. In the next years, an increasing number of studies revealed the 
presence of almost every translation machinery component in the dendrites, including 
tRNAs, initiation and elongation factors, endoplasmic reticulum, Golgi cisternae and 
elements of the co-translational signal recognition mechanism (Tiedge et al. 1996; 
Gardiol et al. 1999; Horton et al. 2003), as well as a restricted group of mRNAs 
encoding for proteins considered crucial for synaptic plasticity (Steward 1997; Tongiorgi 
et al. 1997; Kuhl et al. 1998). Based on this data, and on an early study by Feig and 
Lipton (Feig et al. 1993) in which electrical stimulation was found to induce new protein 
synthesis (labelled with [3H] leucines) in the dendrites but not in the cell body, several 
works in the last ten years focused their attention on local protein synthesis using 
different techniques. In one of these studies, production of genetically modified mice 
with a mutation able to disrupt the dendritic targeting of CaMKIIα mRNA (an important 
gene involved in plasticity) produced a reduction in LTP and an impairment of spatial 
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memory, associative fear conditioning and object recognition memory (Miller et al. 
2002). Another research group, using the 5’and 3’untranslated regions of the same gene 
flanking the coding sequence of green fluorescent protein, created a reporter protein with 
both dendritic localization and translational regulation (Aakalu et al. 2001). Stimulation 
of hippocampal neurons able to induce LTP, determined an increase in new dendritic 
protein translation revealed with FRAP (fluorescence recovery after photobleaching). 
Moreover, the stimulation of protein synthesis was blocked by a well-known inhibitor of 
protein synthesis (anisomycin) and not observed in untreated neurons. Similarly, 
choosing a mechanical method to isolate dendrites from the cell body, Kang and 
Schuman (Kang et al. 1996) demonstrated that LTP requires protein synthesis and still 
persists after removal of the cell body, strongly suggesting that dendritic local protein 
synthesis is capable to support LTP. Different stimulation protocols leads to the same 
conclusion deducted in this experiment (Cracco et al. 2005; Vickers et al. 2005). Indeed, 
mechanical isolated dendrites from the CA1 region of rat hippocampus treated with 
anysomicin or rapamycin, and then stimulated with two tetanic trains in order to induce 
LTP, showed a decline in potentiation with respect to untreated dendrites. Local protein 
synthesis has been reported to be important also in Long Term Depression (LTD). In an 
elegant work, bath application of an agonist of metabotropic glutamate receptor 
(mGluR) was used to induce LTD in hippocampal slices (Huber et al. 2000), and the 
depression was shown to be not perturbed in isolated dendrites where the cell body was 
mechanically removed. Furthermore, administration of anisomycin or mRNA cap 
analogues resulted in inhibition of the establishment of LTD, whilst inhibition of 
transcription did not affect it.  
Thus, it is becoming increasingly clear how local protein synthesis is a crucial 
mechanism for cognitive processes. Although probably other mechanisms are involved 
in induction, maintenance and modulation of LTP and synaptic plasticity, experimental 
evidence strongly suggests that dendritic synthesis of new proteins is essential for 
memory consolidation. 
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Alterations of cognitive processes and its role in neuropsichiatric disorders 
Even considering only the molecular and cellular mechanisms that control learning and 
memory formation described above, it appears clear that cognitive processes is a high 
complex phenomenon in which interactions between different neuronal districts and 
brain areas need to be extremely fine regulated. Hence, the alteration of only one of the 
numerous pathways implicated may lead to a dramatic effect on the overall capability of 
cognitive performance.   
Cognitive impairment has been extensively described both by psychiatry and 
neurobiology. Psychiatry has tried to define it as a difficulty in learning, memory 
formation and storage, reasoning, judgment, intuition, lack of awareness and insight. 
Conversely, instead of giving a very general description, neurobiology has investigated 
restricted aspects of cognitive deficit, looking for the fundamental mechanisms of the 
impairment. 
Numerous attitudinal and psychological tests are currently used to estimate the degree of 
the dysfunction (table 1).  
It is possible to find alterations of the cognitive pathways in almost all neuropsychiatric 
disorder.  From its earliest conceptualizations, cognitive dysfunction has been viewed as 
a core feature of schizophrenia (Kraepelin, 1919). Over the past 15 years, a wealth of 
evidence has provided support for this view, suggesting that neurocognitive deficit is a 
hallmark of schizophrenia evident, by current estimates, in at least 70% of patients 
(Palmer et al., 1997), both at disease onset (Saykin et al., 1994) and after many years of 
treatment (Harvey et al., 1999). In these patients, basic cognitive functions such as 
learning and memory are altered and often compromised. 
Compared to schizophrenic patients, cognitive impairment is observed in a lesser degree 
in bipolar patients. Nevertheless, the pattern of cognitive dysfunctions is similar in both 
groups (Martinez-Aran et al. 2002; Daban et al. 2006) and seem to persist in the long-
term patients (Balanza-Martinez et al. 2005) in relationship with the history of psychotic 
symptoms (Martinez-Aran et al. 2008). 
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Screening 
 Mini-Mental State Examination  
Attention and executive functions 
 Trail Making Test (TMT) 
Language 
 Street Completion Test  
 BORB  
 VOSP 
Memory 
 Digit span 
 Corsi span  
Speech Test 
Attention 
Spinnler Matrix Attention Test 
 Continuous Performance Test (CPT) 
Bourbon-Wiersma Test 
  
Table 1. List of the most commonly used neuropsychological tests for the evaluation of cognitive 
performances. Tests are grouped by the cognitive function that they measure (screening, 
language, memory and attention). 
 
 
 
Also depression (Mitchell et al. 1996; Potter et al. 2007) and Attention Deficit 
Hyperactivity Disorder (Willcutt et al. 2005) are characterized by compromised mental 
performances. In particular, spatial storage and spatial “central executive” components 
appear most strongly compromised in ADHD, although verbal storage and verbal 
“central executive” functioning are affected as well (Martinussen et al. 2005). 
Various molecular pathways seem to be involved in cognitive impairment. However, 
one of the most intriguingly class of molecules appears to be the neurotrophin family.  
11 
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1.3 The neurotrophins 
 
Working on a mouse sarcoma tumour implanted close to the spinal cord of developing 
chicken, Levi-Montalcini and Hamburger (1953) discovered that it secreted a soluble 
factor inducing the hypertrophy and fiber outgrowth of sympathetic neurons. 
Subsequently, in vitro studies revealed that this factor was a relatively low molecular 
weight protein factor, which was later identified as nerve growth factor or NGF (Levi-
Montalcini et al. 1954; Cohen et al. 1957; Levi-Montalcini et al. 1963). This finding 
opened a new field of research in neurobiology devoted to the identification and 
elucidation of the cellular functions of the so called neurotrophic factors (in which is 
possible to include also other molecules such as: transforming growth factor-_ (TGF-_), 
insulin-like growth factor (IGF), epidermal growth factor (EGF), fibroblast growth 
factor (FGF), interleukin-6, bone morphogenetic protein (BMP), platelet-derived growth 
factor (PDGF)). Among this protein family, the neurotrophins (NTs) is of fundamental 
importance, because of their widespread expression in nearly all neuronal populations in 
the CNS and PNS and because of their well-known physiological role in neuronal 
survival, process outgrowth and regulation of synaptic plasticity.  
Two decades after the identification of NGF as the prototypic NT for PNS neurons, 
another neurotrophic factor was isolated from pig brain, which was named brain-derived 
neurotrophic factor (BDNF) and was found to be highly homologous in protein sequence 
to NGF (Barde et al. 1982; Leibrock et al. 1989). Since then, four additional members of 
the family of NTs have been identified (neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-
4/5), neurotrophin-6 (NT-6) and neurotrophin-7 (NT-7)). NT-6 and NT-7 have been 
found only in fish (Gotz et al. 1994; Lai et al. 1998). 
All NTs are generated as pre-pro-neurotrophin precursors (approximately 240–260 
amino acids long), which are further processed until they are eventually secreted as 
mature homodimeric proteins into the extracellular space (length of monomer: 118–129 
amino acids). The road to reach the extracellular space is characterized by some 
common steps. The mRNA is addressed to ER, the synthesized pro-protein is then 
packed in non-clathrin-coated transport vesicles and finally accumulates in the 
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membrane stacks of the trans-Golgi network (TGN). Here, NTs can be sorted to the 
constitutive pathway, where secretory vesicles are transported by default to cell 
periphery, or to the regulated pathway, dependent upon calcium regulation (figure 3). 
 
 
 
 
 
Figure 3. Schematic representation of BDNF traffic (Lessmann et al. 2003). 
 
 
 
Once secreted, NTs can bind to two types of cell surface receptors, the Trk tyrosine 
kinases and the p75 neurotrophin receptor (p75NTR). Each Trk receptor (Trk A, Trk B 
and Trk C) is preferentially activated by one or more NTs and is responsible for 
mediating most cellular responses.  More specifically TrkA is activated by NGF, TrkB 
by BDNF and NT-4/5, and TrkC by NT-3 (figure 4).  
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Figure 4. NTs binding to their receptor. 
 
 
 
 
Binding of the NT initiates Trk dimerization, transphosphorylation of tyrosine residues 
in its cytoplasmic domain and kinase activation (see figure 5). The phosphotyrosine 
residues function as binding sites for recruiting specific cytoplasmic signalling proteins. 
These proteins may in turn be activated by phosphorylation. Contrarily to Trk receptors, 
p75NTR can be activated by the binding with all the four neurotrophins with 
approximately equal affinity, even if it is lower than Trk receptors. While Trk receptors 
transmit positive signals, p75NTR transmits both positive and negative signals. The 
signals generated by the two neurotrophin receptors can either augment or oppose each 
other, regulating almost all aspects of neuronal development and function, including 
precursor proliferation and commitment, cell survival, axon and dendrite growth, 
membrane trafficking, synapse formation and function, as well as glial differentiation 
and interactions with neurons. Moreover, recent studies have revealed a diversity of roles 
for these factors outside the nervous system, most notably in cardiac development, 
neovascularization and immune system function (Donovan et al. 2000; Kermani et al. 
2005).  
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Figure 5. Simplified diagram of NTs intracellular signalling pathways (Reichardt 2006). 
 
 
For exhaustive reviews on neurotrophins,  see for instance: (Kaplan et al. 2000; Roux et 
al. 2002; Lessmann et al. 2003; Reichardt 2006). 
 
Neurotrophins in learning and memory 
As mentioned before, one of the most important cerebral functions regulated by 
neurotrophins is cognitive processes, especially for what concern learning and memory. 
The first reports indicating that neurotrophic factors modulated this process appeared 
more than a decade ago when the work of two groups demonstrated that epidermal 
growth factor and fibroblast growth factor enhanced LTP in CA1 (Terlau et al. 1989; 
Terlau et al. 1990). Based on these studies, later experiments underlined also the 
implication of NGF, NT-3 and BDNF.  
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NGF did not induce LTP in CA1 (Tancredi et al. 1993), possibly because of the low 
TrkA density in this area, but indirect evidence suggests that NGF may play a role in 
expression of LTP in perforant path granule cell synapses where expression of the 
neurotrophin and its receptor are relatively high (Mrzljak et al. 1993). Furthermore, the 
involvement of NGF in synaptic plasticity was demonstrated using behavioural tasks. 
Rats implanted with cannulae in the CA1 area of the dorsal hippocampus and trained in 
one-trial step-down inhibitory avoidance showed that NGF administration blocks short-
term memory and improves long-term memory (Walz et al. 2005), while infusion of 
NGF into the lateral ventricles of aged rats demonstrated its potential role in improving 
spatial but not episodic memory (Niewiadomska et al. 2006).  
NT-3 was shown to induce potentiation in hippocampus, a finding which was replicated 
in isolated spinal cord (Arvanov et al. 2000). However, NT-3 was found to be not 
necessary for LTP induction (Ma et al. 1999), even if more recently using conditional 
knock-out mice, it was detected a selective impairment in LTP in the lateral, but not 
medial perforant path-granule neuron synapses. Mice also exhibited deficits in spatial 
memory tasks (Shimazu et al. 2006) .  
However, the neurotrophin that seems to be more implicated in cognitive processes is 
BDNF. Acute application of exogenous BDNF enhances synaptic transmission and 
induces a form of potentiation that resembles LTP in CA1 cultures (Kang et al. 1995) 
and CA1 slices (Figurov et al. 1996). The focus of attention on BDNF-induced 
potentiation has intensified with the finding that, in addition to its stimulatory effect in 
vitro, intrahippocampal infusion of BDNF into anesthetized rats leads to potentiation of 
the synaptic response in dentate gyrus (Messaoudi et al. 1998) and is peculiar of the 
transcription-dependent late phase of LTP (Messaoudi et al. 2002), driving the switch 
from the early phase (Pang et al. 2004). Moreover, BDNF is necessary and sufficient for 
the persistence of long term memory storage, as recently demonstrated (Bekinschtein et 
al. 2008). The fundamental role in memory consolidation seems to be dependent upon 
the transcription of the Immediate Early Gene Arc. Indeed, Ying and colleagues (Ying et 
al. 2002) examined the expression of Arc mRNA following BDNF-LTP and it resulted 
to be sharply upregulated. In situ hybridization revealed enhanced Arc expression across 
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the granule cell layer and molecular layer of the dentate gyrus, indicating delivery of 
transcripts to dendritic processes.  
Several scientific evidences deriving from behavioural experiments support the data 
emerging from cellular and molecular studies. Increases in BDNF mRNA and protein 
have been recorded in hippocampus after training in a spatial learning task (Gooney et 
al. 2002) and in dentate gyrus after training in a passive avoidance test (Ma et al. 1998), 
paralleling the changes observed after induction of LTP. Consistently, a rapid and 
selective induction of BDNF expression has been reported in amygdala during 
hippocampus-dependent contextual learning (Hall et al. 2000). In addition, it has been 
shown that behaviour in the water maze test is impaired in mutant mice carrying a 
deletion of one copy of the BDNF gene (Linnarsson et al. 1997), in rats that had 
received an intracerebroventricular infusion of anti-BDNF antibody (Mu et al. 1999) or 
with hippocampal-specific deletion of BDNF (Heldt et al. 2007). 
Considered together, these findings suggest that a deep comprehension of BDNF 
regulation and functions might be of extreme importance in order to elucidate the basic 
aspects of cognitive processes and consequently, the physiopathology of cognitive 
impairment. 
   
 
1.4 Brain-derived neurotrophic factor 
 
Distribution and functions 
Brain-derived Neurotrophic Factor (BDNF), firstly discovered in 1982 by Barde and 
colleagues (Barde et al. 1982), is a member of the family of neurotrophins that is highly 
conserved among several species (Hofer et al. 1990; Rosenthal et al. 1991), is the most 
studied neurotrophin after Nerve Growth Factor (NGF) and is the most abundant in the 
brain. BDNF is widely expressed in the central nervous system, especially in the 
hippocampal formation, cerebral cortex, and amygdaloid complex (Ernfors et al. 1990; 
Ernfors et al. 1990; Hofer et al. 1990; Phillips et al. 1990; Wetmore et al. 1990), and its 
expression increases until reaching a maximal level after birth (Maisonpierre et al. 1990; 
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Friedman et al. 1991; Friedman et al. 1991; Schecterson et al. 1992). Then, the 
expression of BDNF seems not to decline with age (Lapchak et al. 1993; Narisawa-Saito 
et al. 1996; Katoh-Semba et al. 1998). However, BDNF is not only widespread 
distributed in the central nervous system, but its mRNA has been observed in numerous 
other tissues as colon, intestine, leukocyte, ovary, spleen, thymus, testis, pancreas and 
blood (Rosenfeld et al. 1995; Liu et al. 2005; Pruunsild et al. 2007). BDNF almost 
ubiquitary distribution underlines the importance of these molecule in a large number of 
different cellular processes, especially for what concerns neuronal functions. Indeed, this 
neurotrophin is strongly involved in: 
 
• cell proliferation (Zhang et al. 2003; de Groot et al. 2006; Hu et al. 2006) 
• cell survival/cell death (Woo et al. 2005; Pyle et al. 2006; Lipsky et al. 2007) 
• differentiation/phenotype maintenance (Schuhmann et al. 2005; Young et al. 
2007) 
• dendrites and axon arborisation (Lom et al. 2002; Kumar et al. 2005) 
• spines maturation (Murphy et al. 1998; Amaral et al. 2007) 
• synapse maturation (Hu et al. 2005; Shen et al. 2006) 
• synaptic transmission (LTP & LTD) (Aicardi et al. 2004; Lu et al. 2007) 
 
BDNF  gene structure   
All genes encoding neurotrophins have a basically similar structure but among all 
discovered neurotrophins the genomic structure of the BDNF gene is unusually complex. 
Despite the fact that the gene organization and regulation of human and rodent BDNF 
gene expression have received close attention during the last decade, knowledge of the 
structural organization of mouse, rat and human BDNF gene has been well characterized 
only in the last years (Liu et al. 2005; Pruunsild et al. 2007). Each BDNF transcripts is 
composed by non coding exons spliced upstream of a common 3’ exon that encompasses 
the whole coding sequence. The detailed characterization of the rodents and human 
BDNF gene has revealed the existence of four exon clusters, each of them regulated by 
different promoters located upstream of these alternatively spliced exons. These 
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promoters enable a precise regulation of BDNF expression in different cell types or in 
response to different stimuli.  
In detail human BDNF gene spans about 70 kb and encode for 11 exons (Figure 6). 
 
 
 
MOUSE AND RAT BDNF GENE  
 
HUMAN GENE  
 
Figure 6. Comparison between rodent and human BDNF gene. Each roman number represents a 
different exon, grouped in clusters delimitated by the double vertical dash (//). Exons Vh and 
VIIIh are uniquely present in the human gene (Pruunsild et al. 2007).  
 
 
 
Exons II, III, IV, V, Vh, VI, and VIIIh are untranslated exons and translation of the 
transcripts containing these exons starts from the ATG positioned in exon IX. Exons I, 
VII, and VIII contain in-frame ATG codons that could be used as alternative translation 
start sites, leading to the production of protein variants differing for the length of the N-
terminus. Two exons, VIII and VIIIh, are rarely used and always in combination with 
exon V as the 5′ exon. Exon IX, which is always translated, can undergo to alternative 
splicing events, generating transcripts containing variants of exon IX. These variants are 
named “a”, “b”, “c” and “d” or can result from an arrangement of these regions.  
The biological meaning of this complexity has been extensively investigated in our lab. 
Tongiorgi and colleagues demonstrated that BDNF mRNAs are targeted to the distal 
dendrites (>100 micron from the soma) in response to titanic electrical activity or other 
stimuli as BDNF itself (Tongiorgi et al. 1997; Righi et al. 2000). The dendritic targeting 
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was also demonstrated in vivo in animal models of epilepsy (Tongiorgi et al. 2004). 
Interstingly, using in situ hybridization, it was noticed that different transcripts seem to 
have different spatial and temporal localization in the neuronal districts (Chiaruttini et 
al. 2008), suggesting the existence of a spatiotemporal code that links different splice 
variants to different localizations and biological functions. To support this hypothesis, 
very recent submitted data revealed that some mRNAs are implicated in cell survival, 
whilst other splice variants are involved in the regulation of dendritogenesis and 
spinogenesis.   
 
BDNF protein: the importance of the pro region 
As the other members of the neurototrophin family, with whom it shares numerous 
structural features, human BDNF protein is firstly translated in an immature form of 
about 32 kDa (proBDNF) that undergoes N-glycosylation and glycosulfation on residues 
located within the pro-domain of the precursor (Mowla et al. 2001). The pro-domain and 
the mature region are composed by 112 and 119 amminoacids respectively. 
 Despite of the high complexity of BDNF gene (see previous chapter), analyses of the 
predicted translation products of the transcripts revealed they can generate only four 
different protein variants (see figure 7)(Liu et al. 2005). Most of the BDNF mRNAs are 
translated in the previously described protein, named proBDNF1. The transcript 
containing BDNF exon I also encodes a 50-UTR inframe methionine that may serve as 
an alternative translational initiation site for a proBDNF2 that would contain eight 
additional N-terminal amino acids (MFHQVRRV). The transcript called BDNF VIIb 
would be also capable to produce proBDNF3 with an addition of seven amminoacids to 
the N-terminus of proBDNF2. Furthermore, BDNF VII mRNA could undergo specific 
splicing event that leads to the deletion of 48 amminoacids (154-201) within the coding 
region, generating proBDNF4. Finally, in a recent work, it has been hypothesized that 
exon VIII would produce a proBDNF variant with an addition of 73 amminoacids to the 
N-terminus of proBDNF2 (Pruunsild et al. 2007). Possible different localization and 
functions of proBDNF variants are still unknown. 
20 
       Introduction 
 
 
 
 
 
 
To reach the mature form of about 14 kDa, proBDNF variants need to be cleaved by 
specific proteases at the N-terminal Arg-Gly-Leu-Thr57-2-Ser-Leu site and cleavage is 
abolished when Arg54 is changed to Ala (R54A). ProBDNF is also able to generate a 
truncated form of about 28 kDa  that arises by a different processing mechanism than 
mature BDNF and it’s not an obligate intermediate (Mowla et al. 2001). Proteolitic 
cleavage can occur either intracellularly or extracellularly. Intracellular cleavage is 
primarily leaded by furin, a protease owning to the family of convertases and it can takes 
place within the trans-Golgi network and/or immature secretory vesicles (Seidah et al. 
1996). Differently, the extracellular processing of proBDNF can be regulated selectively 
by plasmin and matrix metalloproteinases (Lee et al. 2001). Wherever it is processed, 
proBDNF distribution in the brain seems to almost overlap with mature BDNF 
localization (Zhou et al. 2004).  
proBDNF1
 Figure 7. The four proBDNF variants. Boxes of the same colour represent the same 
amminoacidic sequence. 
 
 
 
Intriguingly, data emerging from recent works suggests that proBDNF is not only a 
precursor of the mature and active form of BDNF, but it also seems to elicit important 
biological functions. This hypothesis firstly derives from the evidence that proNGF, 
another neurotrophin precursor, is able to bind p75NTR with high affinity and to 
promote neuronal apoptosis (Lee et al. 2001). Based on this study, Woo and colleagues 
proBDNF2 
(ex I) 
NH2
NH2
proBDNF3 
(ex VIIB) NH2
pro-BDNF4 
(Δ48aa)NH2
Pro region Mature region 
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(Woo et al. 2005) demonstrated that also proBDNF is capable to induce apoptosis in 
cultured sympathetic neurons through the activation of a complex formed by p75NTR 
and sortilin. Both the receptors were found to be necessary for the induction of cell 
death. Furthermore, proBDNF was also linked to synaptic plasticity and in particular it 
was established that it is able to enhance LTD following binding to p75NTR. 
Taken together, these findings reveal a previously unknown functional role of proBDNF 
opposite to the role played by mature BDNF. Therefore, cell survival and synaptic 
plasticity seems to depend on the right balancing of these two forms.      
 
BDNF in neuropsychiatric disorders and cognitive deficit 
After analyzing BDNF and proBDNF biological functions, it appears clear that this 
molecule play a fundamental role in brain health and in cognitive processes. As already 
discussed, the versatility of BDNF is emphasized by its contribution to a range of 
adaptive neuronal responses: LTP, LTD, certain forms of short-term synaptic plasticity, 
as well as homeostatic regulation of intrinsic neuronal excitability (Desai et al. 1999; 
Asztely et al. 2000; Ikegaya et al. 2002; Santi et al. 2006). Thus, it seems reasonable 
that even a single alteration of its highly complex regulation may lead to a pathological 
condition.  
Numerous experimental evidences indicate that an alteration in BDNF mRNA and 
protein levels could lead to psychotic condition, both in post-mortem tissues and in 
animal models of schizophrenia. In particular, mRNAs levels of BDNF and its receptor 
TrkB have been found to be decreased in prefrontal cortex of subjects with 
schizophrenia (Weickert et al. 2003; Weickert et al. 2005), whilst there is an increase of 
the BDNF mRNA levels in cerebellar cortex (Paz et al. 2006). Similarly, BDNF protein 
levels have been reported to be decreased in hippocampus and increased in cortical areas 
of affected patients (Durany et al. 2001), as well as there is an alteration of BDNF 
pathway in animal models of schizophrenia (Lipska et al. 2001; Ashe et al. 2002). 
Interestingly, BDNF was also found to be linked with cognitive impairment typical of 
many schizophrenic patients (Ho et al. 2006). Ho and colleagues demonstrated that in a 
schizophrenic population, patients carrying the BDNF gene Val66Met polymorphism 
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(that changes a valine into a methionine in position 66) performed poorly in verbal 
memory and visuospatial abilities tests, suggesting that this polymorphism could be 
implicated in the pathogenesis of cognitive impairment in schizophrenia. 
Even if schizophrenia seems to be the neuropsychiatric disorder in which BDNF is 
mostly involved in its pathogenesis, it is possible to find a significative role of this 
neurotrophin also in bipolar disorders and ADHD. Genetic association studies 
enlightened that Val66Val allele frequency is higher in patients with bipolar disorders 
compared to a group of healthy volunteers (Lohoff et al. 2005). Moreover, the 
alternative Val66Met polymorphism was also found to be protective against early onset 
of the psychosis (Geller et al. 2004), confirming indirectly that Val66Val allele seems to 
be a risk factor for developing bipolar disorders. For what concern ADHD, it is known 
that BDNF heterozygous null mutants (Kernie et al. 2000) and BDNF conditional 
knockout mice (Rios et al. 2001) exhibit increased locomotor hyperactivity, which 
mimics the fundamental behavioural characteristics of ADHD. However, association 
studies did not reveal any linkage between the disorder and BDNF polymorphisms (Lee 
et al. 2007; Schimmelmann et al. 2007). 
Conversely, the role of BDNF in major depression is still ambiguous. Analysis of post-
mortem hippocampus showed that BDNF expression is decreased in depressed suicide 
patients (Dwivedi et al. 2003), as well as the kinase ERK (Extracellular Regulated 
Kinase) that regulates a fundamental BDNF signalling pathway  (Dwivedi et al. 2001). 
Other evidence suggesting that BDNF is involved in the pathophysiology of depression 
derives from the observation of the effects of antidepressant drugs. Indeed, it has been 
extensively demonstrated that different classes of antidepressants significantly increased 
the expression of BDNF in the major subfields of the hippocampus, including the 
granule cell layer and the CA1 and CA3 pyramidal cell layers (Nibuya et al. 1995; 
Nibuya et al. 1996). The upregulation of BDNF was found also in post-mortem tissues 
of patients treated with antidepressant nearly to the time of death (Karege et al. 2005). 
Nevertheless, behavioural studies are not so convincing. Although various studies found 
data indicating some depressive-like behaviours in mice lacking BDNF or its receptor 
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TrkB in the forebrain, the effects were small or sometimes not significative (Zorner et al. 
2003; Monteggia et al. 2007).  
The controversial data about the role of BDNF in depression was proposed to be linked 
with the biological effects of its precursor. Considering that proBDNF enhances LTD 
(Woo et al. 2005) and LTD is related with stress-induced depressive-like behaviours 
(Holderbach et al. 2007), it has been suggested that the correct modulation of the ratio 
between mature BDNF and its precursor may play an important part in the pathogenesis 
of depression (Martinowich et al. 2007). This consideration has been proved to be true in 
Alzheimer’s disease, a pathology that shares many common aspects with 
neuropsychiatric disorders. Using post-mortem tissues of the parietal cortex of 
Alzheimer patients, Michalsky and colleagues demonstrated by Western blot that there is 
a selective reduction of proBDNF in affected subjects (Michalski et al. 2003). 
Furthermore, in another study, the same group underlined that this reduction occurs in 
the early stage of the disease and it is positive correlated with loss of cognitive functions 
(Peng et al. 2005). 
Reviewing data about BDNF and its relationship with neuropsychiatric disorders 
emphasizes how little is still known. New scientific findings have shifted the attention 
towards the importance of proBDNF biological functions in these disorders, forcing 
scientists to challenge with the high complex modulation of this protein. Therefore, it is 
very likely that BDNF may be implicated in many more aspects of psychosis not deeply 
investigated yet, as for what concern cognitive impairment. Due to the numerous data 
that indicates the involvement of the neurotrophin in various aspects of psychoses, 
BDNF has always been considered a putative diagnostic and therapeutic marker of 
mental health. Hence, examining BDNF levels in tissues from which it is easy to obtain 
a sample as human serum, could represent a powerful tool for clinical applications.  
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BDNF in the serum: a possible marker of neuropsychiatric disorders and cognitive 
deficit? 
BDNF was firstly identified within the human serum in 1995 by Rosenfeld (Rosenfeld et 
al. 1995), even if in an earlier experiment Yamamoto isolated its cDNA from human 
platelets (Yamamoto et al. 1990). These findings rapidly leaded to the development of 
an ELISA-based test to measure BDNF levels in human blood (Pliego-Rivero et al. 
1997).  Successively, it was shown that blood BDNF is essentially stored in blood 
platelets, from which it can be released into the plasma through activation or clotting 
processes (Radka et al. 1996; Fujimura et al. 2002). Moreover, it was reported that 
BDNF could cross the blood brain barrier (Pan et al. 1998), and that BDNF levels in 
brain and serum underwent similar changes during maturation and aging processes in 
rats (Karege et al. 2002), suggesting that serum BDNF levels may reflect the BDNF 
levels in brain.. Alternative sources of blood BDNF were identified in endothelial cells 
(Nakahashi et al. 2000) and lymphocytes (Noga et al. 2003) but their contribution is 
believed to be marginal compared with the bulk release from platelets. 
The concrete possibility that serum BDNF might proportionally reflect the amount of 
BDNF in the CNS quickly attracted numerous investigations due to the easy 
accessibilities of the samples and the fast and high reproducible measurement method 
for estimate BDNF levels, based on ELISA tests. At the moment, a huge number of 
studies have reported altered levels of this neurotrophin in serum of psychotic subjects. 
Indeed, it has been reported that serum BDNF levels were significantly decreased in 
antidepressant-free patients with Major Depression (Karege et al. 2002; Shimizu et al. 
2003). Similarly, serum BDNF levels are reduced in bipolar disorders (Cunha et al. 
2006; Monteleone et al. 2008), whilst nothing is still known about BDNF serum levels 
in ADHD or in cognitive deficit. Regarding schizophrenia, data emerging from these 
experiments are controversial. Surprisingly, some studies reported no variation of BDNF 
levels in serum of patients compared to healthy human volunteers (Shimizu et al. 2003; 
Jockers-Scherubl et al. 2004; Huang et al. 2006), while other authors found a 
significative decrease (Toyooka et al. 2002; Pirildar et al. 2004; Tan et al. 2005; Grillo 
et al. 2007). Furthermore, a very recent study detected an increase of the total amount of 
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serum BDNF (Gama et al. 2007). Data obtained in these experiments are summarized in 
Table 2: 
 
Paper Healthy control 
(ng/ml) 
Schizophrenic patients 
(ng/ml) 
Variation 
    
Toyooka et al. 2002 11,4±7,7 6,3±3,4 Decrease 
Shimizu et al. 
2003 
28.5±9,1 27.9±12,3 No variation 
Pirildar et al. 
2004 
26,8±9.3 14,19±8,12 Decrease 
Jockers-Scherubl et 
al. 2004 
13,2± 5,2 13,1±5,9 No variation 
Tan et al. 
2005 
9,9±4,3 7,3±2,6 Decrease 
 
Huang et al. 
2006 
14,17 ± 6,86 14,20 ± 6,92 No variation 
Gama et al. 
2007 
0,19±0,08 
(pg/µg protein) 
1,21±0,98 
(pg/µg protein) 
Increase 
Grillo et al. 
2007 
16,9 ± 2,6 10,1 ± 5,2 Decrease 
 
Table 2. BDNF serum levels in healthy human volunteers and schizophrenic patients, as reported 
in recent publications. All values are intended as mean ± standard deviation. 
 
 
The controversial results in the dosage of BDNF in human serum of schizophrenic 
patients suggests that a simple measure of total BDNF could not be sufficient in some 
circumstances to established a relationship between serum levels and the pathology, 
considering the complexity of BDNF synthesis, functions and regulation. As discussed 
in the previous chapter, measurement of proBDNF and the ratio between itself and the 
mature form might be more informative rather than the simple estimate of the total 
amount of BDNF. Addressing these questions could help us to reach a better 
comprehension of the phenomenon, as well as to open new research perspectives in the 
field.
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2. AIM OF THE STUDY 
 
 
 
The role of BDNF in neuropsychiatric disorders and the related cognitive impairment 
has been extensively discussed in the previous section. Existing data suggests that the 
common cellular mechanism that could be altered is the regulation of BDNF protein 
synthesis. Therefore, understanding the molecular basis of the cognitive processes as the 
local protein synthesis in dendrites, trying to correlates them with BDNF protein levels 
in neuropsychiatric disorders and cognitive impairment, may represent the first step for 
the development of new powerful tools for compound screening, as well as for the 
diagnosis and the follow-up of medical treatment of these disorders.      
 
It is possible to summarize this PhD project in two aims, both correlated with industrial 
and clinical applications: 
 
Aim 1) to study the cellular mechanisms of BDNF translation in dendrites; 
Industrial application: development of a cellular assay for the in vitro screening of 
compounds to treat cognitive deficit. 
Aim 2) to study the correlation between neuropsychiatric disorders, cognitive deficit and 
levels of BDNF in the serum. 
Clinical application: development of an ELISA kit for the dosage of BDNF in human 
serum as a biomarker of human cognitive deficits. 
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3. MATERIALS AND METHODS 
 
 
To allow an easier consultation of “Materials and methods”, this section will be divided 
in chapters based on the structure of the next section (“results”). 
 
3.1 Preliminary experiments 
 
Materials 
A 30 base Arc oligoprobe (5’ ATA CAG TGT CTG GTA CAG GTC CCG CTT ACG 
3’), used previously by Pinaud and colleagues (Pinaud et al. 2001), was synthesised by 
Invitrogen (Paisley, UK). dATPα 35S was obtained from Amersham (Chalfont St.Giles, 
UK). Cobalt chloride, 5x reaction buffer and terminal transferase enzyme were 
purchased from Roche (Lewes, UK).   
 
Animal treatment 
Male Sprague-Dawley rats with an arrival weight range of 160-220g were supplied by 
Charles River, UK. These animals were group-housed with 5 rats per cage. All animals 
were treated according to the Home Office guidelines and their use in any scientific 
procedure was fully documented. Animals were given a five-day acclimatisation period 
before their use in any procedure was permitted. 
The dose volume used in this study was 2ml/kg and the dose was subcutaneously 
injected (s.c.). 50.7 mg xanomeline were dissolved in 3.31 ml of 0.9% saline to give a 
concentration of 10mg/kg.  Two dilutions of this top dose were made to give 1 and 
3mg/kg respectively.  0.9% saline was used as the vehicle.  Animals were weighed and 
then administered with drug (1, 3 or 10mg/kg) or vehicle (n=6).   
1 hour post dose, animals were sacrificed, their brains removed and frozen in isopentane 
at -40oC. 
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Preparation of sections 
Coronal sections of 14µm were cut through the prefrontal cortex (bregma 1.78  - 1.54 
mm) and the dorsal hippocampus (bregma -1.58 - -1.82 mm) using a thaw cryostat 
mounted onto Polylysine slides (BDH, Poole, UK) and left to dry. Slides were stored at -
70oC. 
 
Radioactive in situ hybridisation 
 
Preparation of 4% Paraformaldehyde (PFA)  
32 g of PFA were dissolved in 800 ml of DEPC treated phosphate buffered saline (PBS) 
by heating to 55oC with continuous stirring and adding a pellet of sodium hydroxide. 
The solution was cooled, filtered and the pH was adjusted to 7.4. 
 
Preparation of hybridisation buffer 
Hybridisation buffer was made up as follows: 
- 10% dextran sulphate 
- 1x Denhardt’s solution 
- tRNA 0.1 mg/ml (from yeast) 
- 0.1% SDS 
- 0.1% Sarkosyl 
- 50% deionised Formamide 
- EDTA 4mM 
- Tris-HCl pH 7.5 80mM 
- polyA 0.1 mg/ml 
- DNA 0.1 mg/ml (salmon sperm) 
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3’end labelling of Arc oligo with terminal transferase 
The 3’ end labelling was set up by adding the following components to a sterile 1.5 ml 
Eppendorf tube: 
 
- 2µl of 100 ng/µl Arc oligo 
- 8µl of 15 mM cobalt chloride 
- 8µl of 5x reaction buffer 
- 10µl of sterile water 
- 10µl of dATPα 35S 
- 2µl of terminal transferase enzyme (40u) 
 
The reaction mixture was vortexed briefly before incubation in a waterbath at 37oC for 1 
hour. The reaction was stopped by adding 60µl of sterile water. The oligoprobe was 
purified by applying the diluted reaction mixture to a Roche quickspin column and 
centrifuging at 2000 rpm for 4 minutes.  
 
Counting of radioactivity incorporated 
To verify the radioactivity incorporated, 1µl of purified oligoprobe was spotted onto a 
Whatman filter circle and placed in a scintillation vial with 5ml of scintillation fluid. The 
vial was subsequently placed in a scintillation counter for measurement of radioactivity. 
Counts should be in the range of 50 000 - 300 000 dpm/ul. 
 
Pre-treatment of the slides 
Slides were removed from the -70oC freezer and thawed at room temperature.  For each 
animal, four slides were used for ISH, two containing sections through the prefrontal 
cortex and two through the dorsal hippocampus. Slides were fixed in ice cold 4% PFA 
for 10 minutes and then washed twice for 5 minutes in DEPC treated PBS. Following 
washing, slides were laid out in trays ready for hybridisation. 
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Hybridisation 
1 ul of the labelled purified oligoprobe was used per 100 ul of hybridisation buffer and 
100 ul of buffer containing probe was used per slide.  For each pair of slides, one was 
hybridised with the antisense probe and the other hybridised with the sense probe.  The 
hybridisation buffer and probe mixture was vortexed thoroughly and left to stand for ten 
minutes before application to slides.  Slides were coverslipped and incubated in a humid 
chamber overnight at 43oC. 
 
Post hybridisation washes 
Coverslips were removed gently by immersing slides in 2 x SCC (0.3M NaCl, 0.3M 
sodium citrate) at room temperature. Slides were washed at 55oC in decreasing 
concentrations of SSC buffer: 4x SSC 2 x 15 min, 2x SSC 2 x 15 min and 1x SSC 2 x 15 
min. Slides were then dehydrated through increasing concentrations of ethanol (70, 90 
and 100%). After washing, the slides were left to dry thoroughly for several hours. Once 
dry, slides were placed in autoradiography cassettes with Kodak biomax MR film for 
one week with a 14C autoradiographic scale (Amersham, Chalfont St.Giles, UK). 
 
Quantification of Arc mRNA 
Following development of films, images from each film were digitised and captured on a 
computer screen. The software program MCID Elite (Micro Computer Imaging Device, 
Imaging Research Inc., UK) was used to measure the expression of Arc mRNA in rat 
prefrontal cortex and hippocampus. A standard curve was set up using the 14C 
autoradiographic scales and Relative Optical Density (ROD) was converted to nCi/g 
before measuring Arc expression. In the prefrontal cortex, the superficial and the deep 
layers were measured by placing a counting box of defined area onto each digitised 
image. For the deep layer, a 200x800µm rectangular box was used, while for the 
superficial layer the box size was 400x400µm (Fig. 4). 
In the hippocampus, measurements were taken from CA1 and CA3 regions, as well as 
from the whole anatomical area. All hippocampal counting was made by free hand 
drawing around the regions of interest. Measurements were taken from both sides of the 
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brain and each slide contained 2 sections so for each animal, 4 counts were obtained in 
total.  4 corresponding measurements were taken from each control slide and these non 
specific values subtracted before means were calculated for each group. 
 
Statistical analysis 
All data was expressed as the mean expression value in nCi/g for each brain area after 
vehicle or xanomeline (1, 3, 10 mg/kg) administration. The data was analysed with the 
software STATISTICA 6 to assess the statistical significance. An ANOVA with Fishers 
LSD test was performed for both the prefrontal and hippocampal data. P-values of 0.05 
or less were considered to be statistically significant. 
 
3.2 Cellular and molecular mechanisms of cognitive processes 
 
Primary cultures of rat hippocampal neurons 
Primary hippocampal neurons from postnatal Sprague–Dawley rats were made 
according to the method of Malgaroli and Tsien (Malgaroli et al. 1992) with slight 
modifications (Tongiorgi et al. 1997). Hippocampi were dissected from 1 to 2-d-old 
animals (P1-P2). All the dissection was performed in 200 μm kynurenic acid (Sigma, 
St.Louis, MO) and 25 μm 2-amino-5-phosphonovalerate (APV; Tocris Cookson, Bristol, 
UK) on ice. The hippocampi were treated with trypsin (2mg/ml; Sigma) and DNase I 
(0,3mg/ml; Sigma) for 10 min at 37°C to isolate the single cells. Cells were cultured for 
8 d in 5% CO2-humidified incubator, in MEM and Glutamax I with 10% FBS, 7mg/ml 
vitamin B12, 30 μg/ml insulin, and 100 μg/ml bovine transferrin and  10 μM cytosine 
arabinoside (AraC) to halt the proliferation of non-neuronal cells. The cells were then 
plated in 24-well chambers at 2 x 105 cells/well. The medium was changed every two 
days from the second day in culture onwards. 
Post-natal Sprague–Dawley rats were supplied by the Experimental Animal Center 
(CSPA-University of Trieste). Procedures involving animals and their care were carried 
out in accordance with national (Decreto Legge N116, Gazzetta Ufficiale, suppl 40, 18-
2-1992) and international laws and policies (European Community Council Directive 
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86/609,Oja L 358, 1, December 12, 1987; National Institutes of Health Guide for the 
Care and Use of Laboratory Animals, US National Research Council, 1996). All efforts 
were made to minimize animal suffering and to reduce the number of animals. 
 
BDNF-GFP chimeric constructs 
The BDNF isoforms-GFP chimeras were previously cloned in our lab by Cristina 
Chiarruttini, a former PhD student, as described below. RNA extraction from total brain 
was performed following the method described by Chomczynski and Sacchi 
(Chomczynski et al. 1987). Since exon I is slightly expressed in the hippocampus 
(Timmusk et al. 1993), RNA for exon I has been extracted from the whole brain of a rat 
treated for 3 hs with kainic acid (12 mg/Kg). After extraction 1 μg of total RNA was 
subjected to reverse transcription (RT-PCR). The RNA was added to the RT-PCR mix 
containing 5X first strand buffer, 250mM Tris-HCl pH 8.3, 375mM KCl, 15mM MgCl2, 
10 mM DTT, 2 units of RNase inhibitor (Roche Diagnostics), 100ng Primer random 
p(dN)6 (Roche Diagnostics), 200μM dNTPs mix (Promega), 200 units of SuperScriptII, 
Life Technologies, Invitrogen. Then the mix has been incubated at 42°C for 50 min.2 μl 
of the RT-PCR reaction have been added to the PCR mix: 10X Reaction Buffer, 500mM 
KCl, 100mM Tris-HCl, pH 9, 1,5mM MgCl2, 200μM dNTPs mix, Taq DNA polymerase 
0,04units/reaction (all from Promega), specific forward and reverse primers 500nM 
(Celbio) to amplify the different BDNF isoforms. Specific forward primers for each of 
the 5’ exons have been used with a common reverse primer which overlaps to the end of 
the CDS 
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The forward primers are the following: 
 
Exon1 Forw  5’- AATTCTCGAGGGTCTTCCCGCCCTAGCCTGAC 
Exon2c Forw  5’- AATTCTCGAGCGGAGCGTTTGGAGAGCCAGCC 
Exon4 Forw  5’- AATTCTCGAGTGAAGGCGTGCGAGTATTACCTCC 
Exon6 Forw 5’- AATTCTCGAGTCGCACGGTCCCCATTGCGCC 
CDS Forw  5’- GCGCTCGAGATGACCATCCTTTTCCTTAC 
 
The sequence underlined corresponds to the XhoI restriction site for the cloning in 
pEGFP-N1 plasmid (Clontech). The common reverse primer is the following: 
 
CDS Rev 5’- GTCACACGTGTCCCCTTTTAATGGTCAGT 
 
The sequence underlined corresponds to the SacII restriction site for the cloning in 
pEGFP-N1. All the PCR products were cloned in the XhoI and SacII cloning sites of the 
pEGFP-N1 plasmid in frame with the GFP gene. 
  
Neurons transfection 
To transfect the different constructs we chose the method of the Lipofectamine 2000TM 
(Life Technology, Invitrogen). For each well of cells to be transfected, 1 μg of DNA has 
been diluted in 50 μl of MEM without serum and antibiotics. At the same time 2µl of the 
LipofectamineTM solution (1mg/ml) have been incubated in 50 μl of MEM. After 5 min 
the two solutions have been mixed, let for at least 20 min at RT and then added to the 
cells. 24 hrs after transfection the Lipofectamine-DNA mix has been carefully removed 
washing the cells twice with PBS. 
 
Electrical stimulation 
In all the experiments of electrical stimulation, neurons were depolarized at RT with 
oxygenated K-medium (10 mM KCl, 1.8 mM CaCl2z2H2O, 0.8 mM MgSO4z7H2O, 
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101 mM NaCl, 26 mM NaHCO3, 1 mM NaH2PO4z2H2O, 0.7% D-glucose, 15 mM 
HEPES, pH 7.4). 
 
Immunofluorescence 
To analyze the expression of the GFP-chimeras in hippocampal neurons 
immunofluorescence has been performed. Cells were fixed for 15 min with PFA 
4%/PBS at RT, washed twice in PBS and permeabilized with Triton X-100 0,5% in PBS 
(Sigma) for 15 minutes. After two washes in PBS, hippocampal neurons transfected with 
the BDNF-GFP chimeras were incubated 1 hour at RT with anti-GFP antibody (BD 
Living colour) diluted 1:100 in PBS, washed twice and incubated for 1h at RT with the 
secondary antibody 1:100 (ALEXA 488 anti-mouse, Invitrogen). Subsequently, after 
another set of washes, they were mounted on coverslips using the mowiol (Sigma) 
mounting gel. 
 
Dendrites transection and electrical stimulation 
Once identified a healthy apical dendrite of a pyramidal neuron transfected with BDNF-
GFP contructs, complete transection of the dendrite was performed lowering down 
carefully a micropipette until the dendrite was pinched. After allowing the micropipette 
to rest for 1-2 minutes, dendrite was mechanically separated from the cell body with 
slow and repeated movements of the micropipette. This procedure, due to its high 
invasivity, frequently determined dendrite disruption. For this reason, only healthy 
dendrites after transection were utilized for our experiments.   
Severed dendrites were depolarized for 15 min at RT with oxygenated K-medium and 
subsequently images were acquired each 30 seconds for one hour.  
 
Image acquisition,  manipulation and measurements 
Neurons and dendrites images were acquired by a Nikon AXM1200 digital camera on a 
Nikon E800 Microscope with interference contrast-equipped lens and with Fluorescence 
lamp. For immunofluorescence experiments, all images were acquired with the same 
exposure time and background noise was subtracted.  
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Images manipulation was performed using NIH ImageJ software. In particular, dendites 
pictures were stretched using Image J plug-in “Straighten” (Kocsis et al. 1991), allowing 
to take measurements not depending by free-hand drawing but determined by a 
rectangular box. 
For the measurements of the maximal dendritic length reached by GFP chimeras in 
localization experiments, the starting point was considered the intersection of the cell 
body with the beginning of the dendrite. After calibration, a rectangular box was traced 
from this point until the last fluorescent signal detectable along the dendrite, indicating 
the distance in microns from the soma. 
For the definition of the minimal time of KCl stimulation and the demonstration of 
BDNF LPS, fluorescent intensity in intact or severed dendrites was measured as mean of 
grey values inside a constant rectangular box along the dendrites until the last detectable 
BDNF signal. For BDNF LPS demonstration, we calculated a normalized difference 
score (Δfluo/fluo), that indicates the change in dendritic fluorescence as a function of 
time. 
 
Statistical analysis 
Comparisons between two or more groups were performed with Student’s t-test or one-
way ANOVA using Sigma Stat 3.1 software. A p-value of 0,05 was considered to be 
significative. 
 
 
3.3 ProBDNF/BDNF ratio in the serum of schizophrenic patients 
 
Subjects 
40 schizophrenia patients (14 males and 26 females) and 40 healthy volunteers (20 
males and 20 females) were enrolled for the study. All the patients included in the study 
met DSM-IV (American Psychiatric Association, 1994) criteria for schizophrenia. The 
diagnosis of schizophrenia was made independently by at least two experts. Average age 
of schizophrenic subjects and control group were 47.2 ± 10.5 and 43.1 ± 8.4 
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respectively. To assess whether the pharmacological treatment influenced BDNF levels, 
we enrolled patients under atypical (32 subjects) and typical (8) antipsychotic drugs 
treatment. Blood sampling was constantly performed in the early morning around 8 am.   
 
Measurement of total serum BDNF 
For serum samples preparation, blood (5ml) was collected in anticoagulant-free tubes 
and maintained at room temperature for 1 hour, followed by 1 hour at 4 ºC to allow 
complete release of BDNF from platelets. Finally, serum was isolated by centrifugation 
at 2000 g for 10 min at 4 ºC. BDNF serum samples were stored within a period of 2 
months at -20 ºC until the collection of the whole samples of the different groups and 
then analyzed in a single experiment repeated three times. Total serum BDNF was 
quantified using a specific ELISA kit following manufacturer protocol (BDNF Emax 
immunoassay system, Promega Co, USA). To determine serum BDNF values, it was 
used a microplate reader (Anthos Labtec Instrument, Chatel-St-Denis, CH) set at 450 
nm.  
 
Western blotting 
Before testing, human albumin and IgG were depleted from serum samples using a 
specific kit (Qproteome Albumin/IgG Depletion Kit, Qiagen, USA) to allow a better 
detection of specific signal, considerably lower than albumin and IgG. Total proteins 
amount in purified serum samples was determined using Bradford assay (Sigma-Aldrich, 
St. Louis, MO, USA)  Samples (30 µg) were then separated by electrophoresis on 12% 
sodium dodecyl sulphate-polyacrylamide gels at 120 V for about 90 minutes and 
transferred onto nitrocellulose membranes (Protran Nitrocellulose Transfer Membrane, 
Whatman, DE) in transfer buffer [39 mM glycine, 48 mM Tris, 0.037% (v/v) SDS, 20% 
(v/v) methanol] at 100 mA for 1 hour. After an incubation of 1 hour at room temperature 
in blocking solution (4% (v/v) non-fat milk powder, 0,05% (v/v) tween-20 in phosphate-
buffered saline) to block non specific signal, membranes were incubated overnight at 4 
ºC with an anti-BDNF antibody (N-20 anti-BDNF, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA; diluted 1:500), capable to detect both the mature and the precursor form 
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of BDNF (Michalski et al. 2003; Peng et al. 2005).  Following washing in blocking 
solution, incubation with anti-rabbit secondary antibody (Polyclonal Goat Anti-Rabbit 
Immunoglobulins/HRP, DakoCytomation, DK, diluted 1:10,000) for 1 hour at room 
temperature and another set of washes, immunoreactive proteins were detected using an 
electrochemiluminescence system (Amersham Biosciences). 
 
Cognitive tests 
Cognitive tests were performed to evaluate cognitive performances in schizophrenic 
patients. A brief description of the tests is reported below: 
 
Speech test (bisillabic words) 
This test is widely used for measurement of working memory. Each trial was composed 
by a set of bisillabic words (from 2 to 9) of increasing length. For each length, there 
were presented 3 word sequences. The patient had to repeat all the elements of the 
sequences in the right order. After a correct answer, the sequence length was increased 
until a mistake. Score was calculated as the maximum sequence length correctly 
repeated by the subject.   
 
Trail making test 
The test consisted of two parts, A and B. Part A consistsed of encircled numbers from 1 
to 25 randomly spread across a sheet of paper. The object of the test was for the subject 
to connect the numbers in order, beginning with 1 and ending with 25, in as little time as 
possible. Part B required the subject to connect numbers and letters in an alternating 
pattern (1-A-2-B-3-C, etc.) in as little time as possible. Scores were calculated by adding 
the time spent by the subject to complete Part A with the time spent to complete Part B. 
This test was used to evaluate attention deficit of the subjects. 
 
Digit span test 
Digit span is a common measure of short-term memory. The test required subjects to 
repeat a string of number starting from one digit. After each correct answer, another 
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single digit was added to the string until patients did not make mistakes. Scores were 
calculated as the number of digit remembered correctly. 
 
Matrix test 
The test evaluates the screening abilities in a specific visual context. Each trial was 
composed by three matrix of increasing difficulty with 13 rows of 10 digits (from 0 to 9) 
each. In a maximal time of 60 seconds, the score was calculated as the total number of 
correct rows filled by the patient (for a maximal score of 60). 
  
  Densitometry and statistical analysis 
Densitometry of immunoreactive bands was determined by scanning films using an 
Epson Scanner (Epson perfection V500 photo) and NIH Image J software.  
For measurement of total serum BDNF and proBDNF/BDNF ratio, each set of data was 
statistically analyzed using one-way ANOVA and pairwise multiple comparison 
procedure (Holm-Sidak). To correlate cognitive performances with proBDNF/BDNF 
ratio, we utilized Spearman correlation.  
Each statistical analysis was performed using Sigma Stat 3.1 software. A P value of 0.05 
was set as level of statistical significance. 
 
 
3.4 Development of an ELISA kit for the dosage of proBDNF/BDNF ratio 
 
Antibodies design and antigenic peptides synthesis 
Identification of the antigenic sites of BDNF was performed using two different 
softwares (JaMBW, Peptideselect design tool-Invitrogen) for the evaluation of antigenic 
and hydrophobic indexes. To estimate the antigen exposure on the surface of the 
molecule, we analyzed a cristallografic structure of BDNF (Robinson et al. 1995) with 
Protein Explorer software. The synthesis of the immunogenic peptides, based on the 
antigenic sequences previously identified, was externalized (EzBioLab, USA). In details, 
we designed eight antibodies reactive against the following BDNF sequences: 
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 Mat 1-12: HSDPARRGELSV-C 
 Mat 91-102: TMDSKKRIGWRF-C 
 Pro total: DEDQKVRPNEENNKD-C 
 Pro1: TMVISYFGC 
 Pro2: C-FHQVRRV 
 Pro3: C-FHQVRRV 
 Pro4 inside del: MQSREEW-C 
 Pro 4 outside del: EKVPVSKGQLKQY-C 
 
Cysteine was added for allow peptide cross-linking to a resin for the purification of the 
specific IgGs. 
 
Antibodies production 
For this step, we adopted a double strategy based on the home made production and on 
the externalization of the entire process (Pacific Immunology, USA).  
The protocol for antibodies production of Pacific Immunology is property of the 
company and it was not revealed.  
For the home made production, antigenic peptides were conjugated with Keyhole 
Limpet Hemocyanin (KLH), a carrier-protein that increases peptides antigenicity. 
Briefly, 6 mg of lyophilized KLH were dissolved in170 µl of borate buffer 0,1 M pH 10 
and mixed in agitation with 2 mg of peptide previously dissolved in 50 µl of borate 
buffer. 80 µl of glutaraldheyde 0,3% in borate buffer were added drop by drop and 
solution was left 1 hour at RT. Subsequently, there were added 50 µl of glycine and the 
solution was incubated another hour at RT. Finally, PBS was added up to 2 ml and the 
solution was dialyzed overnight at 4º. 
After conjugation, 200 µg of immunogenic peptide were mixed in 1ml of physiological 
solution with Freund’s adjuvant and injected intramuscular in New Zeeland White 
Rabbits after local anesthetization with lidocaine. Collection of iperimmune serum was 
obtained from posterior marginal vein of rabbit’s ear. We collected 20 ml of iperimmune 
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serum for the first bleed and a maximum of 50 ml for the following bleeds. After the 
tenth bleed, rabbits were exanguinated obtaining a final bleed of about 100 ml. 
 
Antibodies purification 
Purification of the specific IgGs was performed in column, immobilizing the peptide on 
a suitable resin (Sulfolink Coupling Gel, Pierce, USA). Immunoglobulin purification 
was made accordingly to the manufacturer protocol and checked on SDS 12% 
polyacrylamide gel. 
 
Cell cultures 
Human epithelial kidney cell line 293T (HEK) were cultured in Minimum Essential 
Medium with Earle’s salts and Glutamax I (MEM, Life Technologies, Invitrogen; (Eagle 
1959)) with 10% foetal bovine serum (FBS) in 5% CO2-humidified incubator.  
For transfected cells, the day before transfection, trypsinized and counted cells were 
plated at 5 x 105 cells per well in 6-well plates, in order to have the cell’s monolayer at 
90-95% of confluence on the day of transfection. After 24 hrs they were analyzed by 
fluorescence and subsequently, after a quick wash in PBS, cells were lysate on ice in 
lysis buffer (137mM NaCl, 20mM Tris HCl pH 8.0, 1% NP-40, 10% glycerol, 1mM 
PMSF, 10µg/ml aprotinin, 1µg/ml leupeptin, 0.5mM sodium vanadate) and protein 
concentration was quantified by Bradford method according to the manufacturer 
protocol (Sigma, USA). 
SK-N-BE derived from an human adrenal neuroblastoma with n-myc 100 x amplified 
(high growth rate).The neuroblastoma cell lines were cultured in Dulbecco’s modified 
Eagle’s medium (D-MEM), 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 
U/ml penicillin, and 100 g/ml streptomycin at 37°C with 5% CO2. In order to induce 
permanent neuronal differentiation, 5 µM retinoic acid (RA) final concentration has 
been added to cultures at the time of plating, and replaced every 48 hr. Transfection and 
lysis were performed equally to HEK 293T protocol. 
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Cell transfection 
Cells were transfected with Lipofectamine 2000 TM method. For more details, see the 
correspondent paragraph in chapter 3.2 
 
Dot blot 
Immunogenic peptides or SN-K-BE lysate were spotted at different concentrations (0,1; 
0,5; 1 and 5 µg) on Protran Nitrocellulose Transfer Membrane (Whatman, Germany) 
and left to dry 30 minutes at RT prior the immobilization with glutaraldheyde 0,3 % in 
PBS for 1 hour. After three PBS washes, membranes were blocked for 1 hour at RT with 
blocking solution (4% non-fat milk powder, 0,05% (v/v) tween-20 in PBS). Then, 
membranes were incubated 1 hour at RT with the correspondent antisera diluted 1:100 in 
blocking solution, washed three times and incubated for another hour at RT with 
secondary antibody (Polyclonal Goat Anti-Rabbit Immunoglobulins/AP, 
DakoCytomation, DK, diluted 1:1500). After another set of washes, membranes were 
developed with NBT/BCIP solution (Sigma, USA). 
 
Western blot 
Western blot protocol was performed as described in chapter 3.3.  
For transfected HEK 293T western blot experiments, we performed serial dilutions of 
primary antibodies to establish the suitable concentration. In particular, Mat 1-12 
optimal dilution was found to be 1:1500 dilution and pro total optimal dilution was 
determined as 1:1000. The other immunoglobulins against the different proBDNF 
variants were tested in a range of concentrations starting from 1:100 until 1:5000. Anti-
GFP antibody was diluted 1:1000 and Alomone anti-BDNF and anti-proBDNF were 
used at a dilution of 1:1000 and 1:500 respectively. 
For SN-K-BE experiments, custom and Alomone anti-BDNF antibodies were used at the 
same concentrations utilized for HEK 293T experiments. 
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ELISA 
The day before the experiments, ELISA plates (Corning, USA) were coated with the 
antigens overnight at 4º. The day after, plates were washed with PBS and blocked 1 hour 
with polypep (Sigma, USA) 1% in PBS at RT. After blocking, plates were incubated 1 
hour at RT with the different polyclonal antibodies against BDNF. For competition 
studies, soluble antigens were addede to the plates contemporary to the primary 
antibody. Plates were then washed five times with PBS and incubated with secondary 
antibody conjugated with HRP (Euroclone, Italy) diluted 1:1000. After another set of 
washes, plates were developed with TMB (Euroclone, Italy) for 30 minutes at RT. 
Samples absorbance was read t 450 nm with a microplate reader (Anthos Labtec 
Instrument, Chatel-St-Denis, CH).  
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4. RESULTS 
 
 
4.1 Preliminary experiments  
The PhD project intended to evaluate possible biomarkers of cognitive processes, in 
order to identify the most suitable for the development of an in vitro assay capable to 
individuate cognition enhancing properties of new compounds. Considering that Arc is 
an immediate early gene usually present at very low basal levels, is robustly induced 
upon strong neuronal activity, and the newly synthesized mRNA is rapidly delivered 
into dendrites following NMDA receptor activation or spatial memory tasks (Steward et 
al. 1998; Guzowski et al. 1999), we firstly hypothesized that this gene could be 
appropriate to our purposes. Therefore, we tried to link Arc with cognition through the 
measurement of its mRNA expression in rats after the administration of xanomeline, a 
selective agonist of the muscarinic acetylcholine receptor type 1 (M1 receptor). M1 
receptor was chosen because its activation is strongly involved in cognitive processes 
(Anagnostaras et al. 2002), especially for what concern the cognitive impairment 
associated with neuropsychiatric disorders such as schizophrenia (Dean 2004).   
 
Test of Arc oligoprobe for radioactive in situ hybridisation 
Arc mRNA expression was tested through radioactive in situ hybridisation. To ensure 
the quality and the specificity of the oligoprobe before using it for the in situ 
hybridisation, a small amount was hybridised to rat brain sections from untreated control 
animals.  
A typical Arc expression pattern with minimal background was revealed in the forebrain 
of control animals. Other brain sections, hybridised with a Arc sense probe, revealed a 
barely undetectable signal (figure 8). 
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Figure 8. Arc oligoprobe test in rat prefrontal cortex and the hippocampus. Sense probes did not 
have any reactivity in control slides (right panel). Antisense probes detected the expected Arc 
expression pattern in the different brain area (left panel). 
 
  
Arc expression following administration of the M1 receptor agonist xanomeline 
To determine whether Arc mRNA expression increases after xanomeline injection, a 
total of 10 animals for each dose of the compound (1, 3, 10 mg/kg) and for the control 
(injected with vehicle) were sacrificed 1 hour post dose. Two different brain areas 
related with cognitive functions, prefrontal cortex (pfctx) and hippocampus, were 
investigated.  
 
Prefrontal cortex (pfctx) 
The expression of Arc mRNA was shown to be statistically significant increased in the 
deep layer of the prefrontal cortex following acute administration of xanomeline (figure 
9). The Arc response appeared dose-related in this brain region (significative only for 3 
and 10 mg/kg of the agonist). Expression in the superficial layer was not significantly 
increased.  
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Figure 9. Arc expression in the prefrontal cortex (pfctx) after administration of xanomeline. In 
the left panel, it is shown Arc expression in control (left) and in animal treated (right) sections, 
both for the antisense (up) and the negative control sense (down) probes. In the right panel, the 
graph reports Arc expression densitometry in prefrontal cortex and in the deep layer of prefrontal 
cortex after administration of different doses of xanomeline. There is a significative increase 
(p<0,05) in the deep layer of the pfctx in a dose-dependent manner (for 3 and 10 mg/kg of 
xanomeline). For densitometry measurements, a standard curve was set up using the 14C 
autoradiographic scales and Relative Optical Density (ROD) was converted to nCi/g before 
measuring Arc expression. As=antisense, xan=xanomeline. 
 
 
Hippocampus 
The expression of Arc mRNA was measured in the hippocampal CA1 and CA3 fields as 
well as the dentate gyrus in response to xanomeline administration (1, 3, 10 mg/kg). 
Although an increase in Arc expression at 1 and 3 mg/kg was observed in the CA1 field, 
these increases were not significant and no changes in Arc expression were observed 
either in the CA3 field or the dentate gyrus (figure 10) 
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Figure 10. Arc expression in the hippocampus after administration of xanomeline. In the left 
panel, it is show Arc expression in control (left) and in animal treated (right) slides, both for the 
antisense (up) and the negative control sense (down) probes. In the right panel, the graph reports 
Arc expression densitometry in hippocampus CA1, CA3 and DG areas after administration of 
different doses of xanomeline.There is no significative increase in any brain area investigated. 
For densitometry measurements, a standard curve was set up using the 14C autoradiographic 
scales and Relative Optical Density (ROD) was converted to nCi/g before measuring Arc 
expression. As=antisense, xan=xanomeline. 
 
 
The controversial results obtained with Arc, convinced our group to shift towards other 
possible biomarkers of cognitive processes. Based on the literature data described in the 
introduction, as well as on the previous studies carried out in our laboratory, we decided 
to investigate the role of BDNF in mental processes and its possible use as a biomarker 
of cognitive deficit.  
The study was divided in two parallel approaches, one focused on the investigation of 
the cellular and molecular mechanisms of cognition driven by BDNF (AIM 1), and the 
other based on the analysis of BDNF protein levels in the human serum and their 
relationship with cognitive performances (AIM 2). Possibly, each of the two projects 
should lead to industrial and clinical applications. 
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4.2 Cellular and molecular mechanisms of cognitive processes 
BDNF mRNA is known to be delivered to different subcellular compartments, 
depending on the splice variants that are considered (Chiaruttini et al. 2008), and 
different splice variants seems to be involved in different cellular functions (laboratory 
unpublished data). Hence, we hypothesized that also the corresponding translation 
products could be preferentially localized in different neuronal districts. 
 
Localization of BDNF proteins generated by different mRNA splice variants 
To study the localization of BDNF proteins, four chimeric BDNF-GFP constructs 
bearing alternatively exon 1, 2c, 4, 6 or the coding sequence were used. Hippocampal 
neurons (7DIV) were transfected with the constructs, fixed with PFA and then 
immunostained with an antiGFP antibody.  
To ensure that the immunostaining of the neurons was entirely due to BDNF and not to a 
technical artefact, we transfected hippocampal neurons with GFP alone, and then the 
staining pattern of the anti-GFP antibody was compared to that of GFP autofluorescence. 
GFP immunostaining perfectly overlapped the autofluorescence of the GFP (figure 11).  
 
 
Figure 11. Comparison between GFP autofluorescence (green) and immunofluorescence against 
GFP (red) in hippocampal neurons (7 DIV) transfected with GFP. Immunofluorescence staining 
completely overlap GFP autofluorescence (yellow). 
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The immunofluorescence for the BDNF-GFP chimeric constructs using an anti-GFP 
antibody, revealed that they are differently distributed within the soma or the dendrites 
(figure 12).  
 
   
Figure 12. Subcellular localization of BDNF proteins translated from 5 different BDNF mRNA 
splice variants. Hippocampal neurons (n=20 for each group) were transfected with BDNF-GFP 
plasmids containing either exon 1, 2C, 4, 6 or CDS (coding sequence) and immunostained with 
antiGFP antibody. In the upper panel, there is a comparison between the length of the dendritic 
staining of different BDNF proteins and mRNAs splice variants. The maximal distance from the 
soma reached by the dendritic staining was measured starting from the beginning of the dendrite 
(white arrows) until the last BDNF signal along the dendrite could be detected (red arrows for 
the protein, black arrows for the mRNA). In the lower panel, the probability plots (percentage of 
transfected neurons where BDNF signal reaches an established dendritic length) of dendritic 
staining shows a clear correlation between the localization of BDNF-GFP proteins and mRNAs. 
Exon 1 and 4 revealed to have a somatodendritic distribution, while exon 2c, 6 and CDS were 
preferentially localized in the distal dendrites.  
 
 
Exon 1 and exon 4 BDNF-GFP chimaeras are predominantly restricted to the 
somatodendritic subfield (50% of the protein within the first 15 µm or 45 µm 
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respectively), while exon 2c, exon 6 and CDS BDNF-GFP constructs are delivered 
throughout the proximal and the distal dendrites (50% of the protein within the first 70 
µm for exon 2c and 6, 85 µm for CDS). 
The protein localization is substantially comparable to the distribution of the 
correspondent mRNA splice variants, except for exon 4 in which the mRNA seems to be 
distributed closer to the soma than the corresponding chimeric protein (50% of the 
mRNA is localized within the first 15 µm, whilst the protein is distributed around the 
proximal 45 µm of the dendrite. However, both the mRNA and the protein originating 
from exon4 variant could be considered to have somatodendritic localization. 
 
Demonstration of BDNF Local Protein Synthesis in dendrites 
Once established that BDNF splice variants are differentially distributed and the protein 
products that they generate have a distribution similar to the cognate mRNA, we 
investigated whether these mRNAs could be translated locally into dendrites following 
electrical stimulation. To determine the minimum time required to induce a detectable 
increase in protein synthesis, we stimulated with KCl hippocampal neurons transfected 
with exon 6 BDNF-GFP plasmid and immunofluorescence was measured at different 
times (3, 10, 15, 30, 45 and 60 minutes). Results demonstrated that the total fluorescent 
intensity along the whole dendrite was maximal after 15 minutes of stimulation (figure 
13) and the declined rapidly at subsequent times.  
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Figure 13. Definition of the minimum time of KCl stimulation required to induce an increase in 
BDNF protein synthesis. Hippocampal neurons (n=20) were transfected with exon 6 BDNF-
GFP, stimulated with KCl for different times and fixed prior the immunofluorescence detection 
of BDNF expression (determined as mean of gray values along the whole dendrite). It was 
noticed a significative increase of protein signal (p<0.05) after 15’ of KCl stimulation. 
 
 
To demonstrate that BDNF mRNAs can be translated within the dendritic compartment, 
first hippocampal neurons were transfected with either a somatodendritic or a distal 
dendritic chimerical construct (exon 4 or exon 6 BDNF-GFP), and then the dendrites 
were separated mechanically from the soma using a micropipette. For this set of 
experiments, only healthy severed dendrites were considered. This preparation allowed 
to examine unambiguously the local synthesis of proteins in dendrites, without 
contribution of protein transport from the soma. 
Stimulation of healthy transected dendrites with KCl for 15 minutes produced an 
increase in protein synthesis reaching the peak 20 minutes after the stimulation (figure 
14).  
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Figure 14. Demonstration of exon 6 BDNF-GFP Local Protein Synthesis in cut dendrites. Upper 
panel shows a severed dendrite from a neuron transfected with exon 6 BDNF-GFP construct at 
different times after stimulation with KCl. The increase in protein synthesis is especially focused 
in “hot spots”. The graph in the lower panel compares the normalized fluorescence intensity 
along the whole dendrite in not stimulated and electrically stimulated dendrites at different time 
points. Fluorescence intensity is the mean of 7 severed dendrites.   
 
 
The increment in BDNF-GFP fluorescence was detectable only in dendrites of neurons 
transfected with exon 6 BDNF-GFP construct and not in dendrites from neurons 
transfected with exon 4 BDNF-GFP (figure 15). 
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Figure 15. Study of the local protein synthesis of exon 4 BDNF-GFP. Upper panel shows a 
severed dendrite from a neuron transfected with exon 4 BDNF-GFP construct at different times 
after stimulation with KCl. There is no increase in the fluorescent signal, indicating that this 
plice variant is not able to be synthesized locally. The graph in the lower panel compares the 
normalized fluorescence intensity along the whole dendrite in not stimulated and electrically 
stimulated dendrites at different time points. Fluorescence intensity is the mean of 7 severed 
dendrites. 
 
 
 
 BDNF protein synthesis occurred mainly in spots located at different distances along 
the dendrites. The spot intensity was found to be maximal 15 minutes after stimulus, 
rapidly decaying within the next 15 minutes (figure 16). Treatment of the dendrites with 
an inhibitor of protein synthesis (cyclohexymide) prior the stimulation completely 
blocked the signal increase, indicating that it was due to effective protein synthesis 
rather than protein redistribution. 
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Taken together, these findings demonstrate that BDNF mRNA can be directly translated 
into dendrites.  
  
 
 
Figure 16. In the upper panel it is possible to appreciate the fluorescence intensity of a single 
“hot spot” of exon 6 BDNF-GFP synthesis in a severed dendrite at different times of KCl 
stimulation. The graph in the lower panel represents the mean of fluorescence intensity of 10 
“hot spots”. 
 
 
 
Future perspectives: LPS and industrial applications 
The results showing that we are able to detect BDNF local protein synthesis, which 
represents one of the major mechanisms involved in cognitive processes, suggested us 
the possibility of utilize this assay for industrial applications. In particular, LPS might 
result an important biomarker for cognition enhancing properties of developing 
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compounds. Considering that drug screening process is always looking for innovative 
biomarkers, we are developing a semi-automated method capable to detect LPS that is 
the core of an industrial project in the drug screening field (figure 17). At the moment, 
we are optimizing the creation of the physical support needed for the screening. 
This industrial project is supported by a business plan that was awarded in the “StartCup 
2007” competition as one of the best ten projects of the university of Trieste (NeuroScrin 
Project). 
 
Figure 17. Schematic representation of the semi-automated method for the detection of LPS in 
drug screening process. Hippocampal neurons transfected with a fluorescent reporter are plated 
into a square canal, forcing the neurite to grow in a upper layer (left panel). Afterwards, neurons 
are separated from the soma using an automated “dendrite cutter” and stimulated with 
developing compounds for the automated detection of the LPS signal.   
 
 
 
4.3 ProBDNF/BDNF ratio in the serum of schizophrenic patients. 
Simultaneously to the investigation of the cellular and molecular mechanisms of 
cognitive processeses, the PhD project focused on BDNF protein levels in human serum 
as another potential biomarker of cognition and mental health. To provide a proof of 
concept of this idea, we decided to examine a group of patients suffering of 
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schizophrenia, the neuropsychiatric disorder with the highest incidence of cognitive 
impairment, studying the correlation between BDNF serum levels and their cognitive 
performances. 
 
Total BDNF levels in the serum of schizophrenic patients 
To elucidate whether there is an alterations of total serum BDNF in schizophrenic 
patients, we analyzed with a commercially available ELISA kit two groups of subjects 
consisting in 40 healthy human volunteers and 40 age matched schizophrenic patients. 
Blood samples collected, after coagulation at room temperature, were left 1 hour on ice 
to induce a stress response capable to induce BDNF release in the serum from platelets.  
Table 3 shows the demographic data and the BDNF serum levels of the two samples, 
underlining that there is no statistically significative difference between the control 
group and schizophrenic patients (p=0.558, One-way ANOVA). 
 
 Healthy human volunteers 
(n=40) 
Schizophrenic patients 
(n=40) 
Age 43.1 ± 8.4 47.2 ± 10.5 
Gender (M/F) 20 M / 20 F 14 M / 26 F 
Antipsychotic 
treatment 
No 32 atypical 
8 typical 
BDNF serum 
values (ng/ml) 
25.2 ± 7.74 M / 28.9 ± 4.2 F 
total mean: 26.5 ± 8.12 
24.3 ± 5.8 M/ 27.3 ± 6.5 F 
total mean: 25.3 ± 6.54 
 
Table 3. Demographic data and BDNF serum values of the sample. All values are intended as 
mean ± standard deviation. 
 
 
 Serum concentration of total BDNF in control group was 26.5 ± 8.12 ng/ml (mean ± 
standard deviation), while in schizophrenic subjects corresponded to 25.3 ± 6.54 ng/ml. 
The median of the two groups (28.8 and 26.06 ng/ml respectively) and values 
distribution are reported in Figure 18. Moreover, as reported previously (Ziegenhorn et 
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al. 2007), we did not detect significant gender difference between BDNF serum values 
of male (25.2 ± 7.74 ng/ml) and female (28.9 ± 4.2 ng/ml) healthy donors (p=0,144, 
One-way ANOVA). 
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Figure 18. Box plot of BDNF serum values (ng/ml) in healthy human volunteers (n=40) and 
schizophrenic patients (n=40). There is no statistically significative difference (p=0.558) 
between the two groups of subjects. The upper line of the box corresponds to the 75th percentile, 
the middle bold line is the median value and the lower line marks the 25th percentile. Whiskers 
(error bars) above and below the box indicate the 90th and 10th percentiles respectively. 
 
Measurement of the ratio proBDNF/BDNF in the serum of schizophrenic subjects  
Since we did not find any alteration of the total BDNF in the serum of schizophrenic 
patients, we hypothesized  that the correct balance between proBDNF and mature 
BDNF, which elicit opposite biological effects on the nervous system, might be altered 
in schizophrenia, possibly leading to the cognitive deficit related with this disorder. 
Consequently, we firstly demonstrated through Western Blot technique using an 
antibody able to recognize both the precursor and the mature form (N-20, Santa Cruz), 
that proBDNF is present at detectable levels in human serum. To allow the detection of 
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proBDNF, it was necessary to clear the samples from albumin and IgG, which constitute 
the predominant portion of the protein population in human serum (see Matherials and 
Methods, chapter 3.3). Thanks to this purification step, we were able to load a sufficient 
amount of sample in order to recognize proBDNF band. Competition experiment, in 
which the antibody was pre-incubated with the peptide used to produce the 
immunoglobulin, confirmed the specificity of the signal (figure 19). 
 
 
Figure 19. Specificity of N-20 antiBDNF antibody. The immunoglobulin was able to recognize 
recombinant BDNF (250 pg), recombinant BDNF (250 pg) and the two forms of BDNF in 30 µg 
of human serum proteins (left panel, from left to right). Detection of recombinant BDNF and 
proBDNF, as well as BDNF bands in the serum were abolished by incubation of the primary 
antibody with a 50-fold excess of specific blocking peptide (right panel) 
 
 
Once established that proBDNF is measurable in human serum, we examined by 
Western Blot the serum samples of both schizophrenic and healthy volunteers group 
(figure 20). Band densitometry (with background noise subtraction) allowed us to 
measure the ratio between proBDNF and mature BDNF, finding a significant reduction 
of this ratio in psychotic subjects compared to the control group.  
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Figure 20.  Western blot of serum samples from schizophrenic subjects (upper panel, n=20) and 
healthy volunteers (lower panel, n=20). In each lane it was loaded the same amount of serum 
proteins (30 µg) depleted from albumin and IgG. The amount was estimated through Bradford 
method. Pro and mature BDNF are at the expected molecular weight of 32 and 14 kDa. The bar 
graph below reports proBDNF/BDNF ratio in control and schizophrenic subjects, evinced by the 
densitometry of the immunoreactive bands. The ratio proBDNF/BDNF in human serum is 
significantly decreased (p<0.05, One-way ANOVA) in schizophrenic patients (0,04) compared 
to healthy controls (0,19). 
 
 
Correlation between proBDNF/BDNF ratio and cognitive performances 
Considering that BDNF is strongly involved in cognitive processes, we utilized some of 
the most commonly used neuropsychological tests to established whether there is a 
correlation between the decrease of the ratio proBDNF/BDNF and the severity of 
cognitive impairment in schizophrenic patients. All subjects with cognitive dysfunctions 
reported in their clinical history, were examined with four different tests (TMT or Trial 
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Making Test A and B, Digit Span, Speech Test of bisillabic words, Spinnler Matrix 
Attention Test) for the evaluation of attention, short term memory, working memory and 
screening abilities respectively (table 4). 
 
. 
Speech 
Test 
(working 
memory) 
TMT  
A, B 
(attention)  
Digit 
Span 
(short-
term 
memory) 
Matrix  
Test 
60/60 
(screening 
abiity) 
ProBDNF/BDNF ratio 
5 n.s. (not solved) 7 38 0,00 
4 30s 10 53 0,07 
4 n.s. 2 6 0,10 
4 34s 4 51 0,00 
3 n.s. 2 25 0,00 
4 31s 10 58 0,03 
5 60s 10 43 0.00 
4 n.s. 4 15 0.13 
4 30s 4 49 0.03 
5 43s 4 46 0,07 
6 25s 10 43 0,21 
4 20s 7 32 0,00 
5 51s 9 60 0,10 
4 n.s. 4 35 0,18 
5 n.s. 9 50 0,02 
5 25s 9 49 0,00 
4 44s 4 60 0,00 
5 35s 11 60 0,00 
4 56s 9 47 0,00 
4 2,35s 4 23 0,00 
 
Table 4. Cognitive performances of schizophrenic patients and corresponding ratio of 
proBDNF/BDNF in the serum. The table reports the score for each test (Speech Test, TMT A 
and B, Digit Span, Matrix Test) used for estimate attention, short term memory and working 
memory abilities of the subjects.  
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Subsequently, the cognitive performances and the ratio proBDNF/BDNF were correlated 
with Spearman rank correlation. We analyzed separately each cognitive test, finding no 
positive or negative correlation between test scores and proBDNF/BDNF ratio levels 
(figure 21). 
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Figure 21. Correlation between cognitive tests and ratio proBDNF/BDNF in schizophrenic 
subjects (n=20). Spearman rank correlation revealed that there was no positive or negative 
correlation (p>0,05) with proBDNF/BDNF ratio for Speech Test (upper panel, left), TMT Test 
(upper panel, right), Digit Span Test (lower panel, left) and Spinnler Matrix Attention Test 
(lower panel, right).  
 
 
 
Considering that our population was composed by patients treated with different 
antipsychotics that could be divided in two main compound classes (typical and atypical 
antipsychotics), we evaluated if the results were influenced by the pharmacological 
treatment. Although proBDNF/BDNF ratio in patients treated with atypical 
antipsychotics was double in respect of  patients treated with typical antipsychotics, the 
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limited number of subjects analyzed did not allowed us to reach a statistical significance 
(figure 22). 
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Figure 22. Comparison of the ratio between proBDNF and BDNF  in schizophrenic patients 
treated with typical or atypical antipsychotics. There are no significative alterations (p>0,05) 
between the two groups. 
 
 
 
Even though we did not find any correlation with cognitive impairment or 
pharmacological treatment, experimental evidence of a reduced ratio proBDNF/BDNF 
in the serum of schizophrenic subjects convinced us of the importance of this 
measurement at least in schizophrenia.  
However, the available ELISA kits allow only the detection of total BDNF, which we 
showed to have no clinical relevance in schizophrenia. Therefore, we started to develop 
a novel diagnostic kit based on an ELISA platform able to discriminate between the 
precursor and the mature form of BDNF in a rapid and reproducible way. 
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4.4 Development of an ELISA kit for the dosage of proBDNF/BDNF ratio 
The first step for the development of the ELISA kit was the design of polyclonal 
antibodies. In addition to the antibodies against the BDNF pro and mature form, we 
planned the production of four antibodies designed to recognize specifically the four 
different proBDNF protein variants (Pro1, Pro2, Pro3 and Pro 4), in order to investigate 
whether single protein variants might be specifically involved in neuropsychiatric 
disorders and cognitive deficit.   
 
Antibodies design 
To identify BDNF antigenic sites, we evaluated numerous parameters such as 
hydrophobicity and antigenicity index using two different appropriate softwares 
(JaMBW, Peptideselect design tool-Invitrogen). Once recognized the most promising 
sites, we checked their effective exposure on the molecule surface through the analysis 
of the three-dimensional crystallographic structure of mature BDNF (Robinson et al. 
1995; Robinson et al. 1999). Unfortunately, the three dimensional structure of proBDNF 
is not available yet.  
We were able to identify three different high antigenic sites on the mature form, thus we 
decided to utilize each of the three sequences for the antibodies production to ensure the 
maximal chances of success. In summary, we designed eight peptides to create eight 
antibodies able to discriminate between mature BDNF, proBDNF and the four proBDNF 
variants (figure 23). The antibody for the detection of proBDNF4, which is carachterized 
by the presence of a deletion within the mature region, was targeted against a peptide 
containing 5 amminoacids before and five amminoacids after the deletion region, 
recognizing a unique sequence present only in proBDNF4 variant. 
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Figure 23. Schematic representation of the plan for the production of the antiBDNF antibodies 
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Antibodies production 
Each polyclonal antibody was produced starting from the synthesis of a peptide 
corresponding to the antigenic sequence identified as described in the previous 
paragraph (EzBiolab, USA). To maximize our rate of success we followed a double-
chance strategy for the production of the antibodies based either on the home-made 
production or on the externalization of the process. Combination of these two strategies 
allowed us to choose the best antiserum for each of the antibodies planned.     
 
Antibodies validation 
After the final bleed, each antiserum was validated through Dot Blot, Western Blot and 
ELISA techniques. 
 
Dot blot: 
We tested in Dot Blot the eight antisera made with both strategies (a total of 16 
antibodies), in order to establish a battery of the eight best produced. Antisera and their 
corresponding pre-immune antisera were tested against their antigenic peptides and on a 
SN-K-BE (human neuroblastoma cell line) lysate.  
We were able to select one antiserum for each of the antibodies designed capable to 
recognize the corresponding peptide spotted at different concentrations (0,1 µg; 0,5 µg; 
1 µg; 5 µg, see figure 24). Except for Pro total that seemed to have lower affinity for the 
antigen than the others (the signal is detectable only for 1 and 5 µg spots), all antisera 
had a strong reactivity (figure 24). Pre-immune antisera revealed to be almost no 
reactive against the peptides (figure 24), whilst there was a mild response against lysates 
from human neuroblastoma SN-K-BE, a cell line that express BDNF at high levels (data 
not shown). 
 
 
 
 
 
65 
       Results 
 
 
 
 
 
 
                                                                             
0,1µg 0,5µg 
1µg   5µg 
 
 
Figure 24. In the upper panel, schematic representation of the amount of peptide spotted in Dot 
Blot experiments (range of the substrate amount: 0,1– 5 µg). In the lower panel, Dot blot of the 
best antiBDNF antisera and their correspondent pre-immune bleeding, tested on their antigenic 
peptides (range of the substrate amount: 0,1– 5 µg).  
 
 
 
Due to the cross-reactivity of the pre-immune sera against neuroblastoma cells, we 
decided to purify the specific IgGs against BDNF from the antisera through affinity 
purification, immobilizing the antigenic peptides on a suited sepharose column. Purified 
antisera run on 12% polyacrylamide gel revealed that the purification was successful 
(figure 25). 
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Figure 25. Purification of Mat 1-12 antiBDNF antibody. 12 % polyacrylamide gel stained with 
Coomassie Blue of the first two fractions eluited from the purification column. The heavy and 
the light chains of IgGs are at the expected molecular weight. 
 
 
Western blot: 
Purified polyclonal antibodies were tested for BDNF detection both in transfected and 
non transfected cells. To express exogenous BDNF, we utilized HEK 293-T kidney cell 
line because of their high transfection rate and the barely undetectable levels of BDNF 
mRNAs in microarray platforms (pubmed GEO profiles; GDS1852 record). Absence of 
BDNF protein was confirmed by Western blot using commercially available antiBDNF 
antibodies (figure 26, lane 4).  
To validate the antibodies against the mature form (Mat 1-12, Mat 91-102 and Pro 4 
inside), the pro form (pro total) and the Pro1 variant of BDNF, the cell line was 
transfected with a construct encoding for the human proBDNF protein in fusion with 
GFP (CDS BDNF-GFP) with all the epitopes recognized by the different antibodies (see 
Introduction, chapter 1.4). 
Among the antibodies against the mature region, Mat 1-12 revealed to have strong 
affinity in western blot for BDNF-GFP protein (figure 26).  
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Figure 26. Western Blot validation of Mat 1-12 anti-BDNF antibody in lysate (30 µg) of HEK 
293-T cells transfected with CDS BDNF-GFP plasmid. BDNF-GFP protein is expected at about 
62 kDa (32 kDa for BDNF + 30 kDa for GFP). 1, 2, 3, 4 and 5 columns: controls. As expected, 
anti-GFP antibody did not detected BDNF in HEK 293 lysate and recognized GFP and BDNF-
GFP in transfected HEK 293 cell lysate (columns 1, 2 and 3). Also Alomone anti-BDNF 
detected BDNF-GFP in transfected cell lysate (column 5), with no signal in non transfected HEK 
293 (column 4). Mat 1-12 antibody recognized the same bands of Alomone anti-BDNF with 
higher affinity (columns 6 and 7), with no signal for the correspondent pre-immune antiserum 
(column 8).     
  
 
 
In contrast, the antibody against the pro form of BDNF (pro total) demonstrated a 
weaker affinity for BDNF-GFP protein (figure 27), whilst pro1 immunoglobulin failed 
to detect the expected band (data not shown).  
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Figure 27. Western Blot validation of pro total anti-BDNF antibody in lysate (30 µg) of HEK 
293-T cells transfected with CDS BDNF-GFP plasmid. BDNF-GFP protein is expected at about 
62 kDa (32 kDa for BDNF + 30 kDa for GFP). 1, 2, 3, 4 and 5 columns: controls. Anti-GFP 
antibody did not detected BDNF in HEK 293 lysate and recognized GFP and BDNF-GFP in 
transfected HEK 293 cell lysate (columns 1, 2 and 3). Alomone anti-proBDNF detected BDNF-
GFP in transfected cell lysate (column 5), with no signal in non transfected HEK 293 (column 
4). Pro total antibody recognized the same bands of Alomone anti-BDNF with similar affinity 
(columns 6 and 7), even though there was a not specific band at about 70 kDa. Correspondent 
pre-immune antiserum did not show reactivity against BDNF-GFP (column 8). 
 
 
 
The antibody pro1, raised against an antigen common to all the different proBDNF 
variants pro2, pro3 and pro4 immunoglobulins, failed to recognize BDNF when tested 
on HEK 293-T cells transfected with exon 1 (pro2) or exon VII (pro3 and pro4) BDNF-
GFP plasmids, (data not shown). 
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To ensure that data obtained from the previous experiments were not due to technical 
artefacts, we validated the antibodies in the SN-K-BE neuroblastoma cell line that was 
already used for the dot blot experiments. 
Mat 1-12 confirmed to have high affinity for BDNF, both in SN-K-BE lysate and in a 
preparation of purified recombinant human BDNF. Conversely, the antibody against the 
pro region (pro total) revealed an unexpected cross-reactivity with mature BDNF (figure 
28). 
 
 
1                     2                       3                     4                      5                      6 
Figure 28. Western Blot validation of Mat 1-12 and pro total anti-BDNF antibody in SN-K-BE 
cell lysate (30 µg) and on recombinant human BDNF protein. Anti-BDNF Alomone and mat 1-
12 demonstrated high reactivity against recombinant BDNF and proBDNF (columns 1 and 3), 
while anti-BDNF Alomone showed strongest reactivity against mature BDNF of SN-K-BE cell 
lysate than Mat 1-12 (columns 2 and 4). Neither of the antibodies detected proBDNF in the 
lysate. Pro total revealed to have an unwanted cross-reactivity against recombinant mature 
BDNF and mature BDNF of SN-K-BE cell lysate (columns 5 and 6).  
 
 
The antibodies against the four pro BDNF variants failed to detect BDNF both in the 
neuroblastoma cell lysate and in the preparation of purified recombinant human BDNF.  
.ELISA 
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After validation in Dot blot and Western blot, the antibodies that showed the best 
affinity for BDNF (Mat 1-12 and pro total) were analyzed in an immunoenzimatic assay 
(ELISA). Plates were coated either with 100 ng of antigenic peptide or 100 ng of 
recombinant human BDNF and the two antibodies were tested at serial dilutions. It was 
possible to detect a signal at a maximal dilution of 1:12.800 for both antibodies (figure 
29), with intensity trend comparable to the serial dilutions. 
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Figure 29. ELISA test for the validation of Mat 1-12 and pro total anti-BDNF antibodies. Plated 
were coated overnight with 100 ng of recombinant human BDNF and the antibodies were tested 
at different dilutions, starting from 1:200 until 1:12.800.  
 
 
 
Pre-immune antisera did not show any reactivity against BDNF also in ELISA, 
confirming the specificity of the binding of Mat 1-12 and pro total (figure 30). 
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Figure 30 ELISA test of pre-immune antisera of Mat 1-12 and pro total. Plated were coated 
overnight with 100 ng of recombinant human BDNF and the antibodies were tested at different 
dilutions, starting from 1:50 until 1:3.200. Pre-immune antisera did not reveal any reactivity 
against BDNF. 
 
 
These data underlined the good affinity of Mat 1-12 for BDNF and confirmed that pro 
total seems to have an undesired cross-reactivity with recombinant mature BDNF. 
 
 
Development of the ELISA kit for the dosage of the ratio proBDNF/BDNF 
Antibodies validation disclosed that pro total has an unwanted cross-reactivity with 
mature BDNF, forcing us to follow another strategy for the development of the ELISA 
kit for the dosage of the ratio proBDNF/BDNF (see future perspectives).  
At the same time, we performed some pilot studies based on Mat 1-12 to determine the 
most suitable ELISA platform for the assay. Two possible platforms were analyzed. 
Firstly, we investigate whether a competitive structure of the test, in which the amount 
of BDNF in the samples is coated to the ELISA plates and compete with recombinant 
BDNF for the binding with the anti-BDNF antibody, might be suitable for the 
determination of BDNF quantity in the sample. The reason of this choice was related to 
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the possibility to obtain an assay different from those (ELISA “sandwich”) that are 
already present on the market for the detection of total BDNF.  
Hence, we started to produce a BDNF calibration curve to quantify the ability of the 
antibody to compete for BDNF. Plates were coated with 100 ng of recombinant BDNF 
and Mat 1-12 antibody was incubated in the plates with different concentration of 
soluble recombinant BDNF or soluble antigenic peptide. It was possible to obtain a 
satisfactory competition curve, in which the affinity of the antibody for coated BDNF 
decreases as the concentration of soluble competitor increases, only for the antigenic 
peptide and not for BDNF (figure 31). Indeed, the competition curve decreased until 
90% with soluble peptide (optimal result), whilst it reached only the 50% with soluble 
BDNF. These results convinced us to choose for the other ELISA platform. 
 
 
 
Mat 1-12 + BDNF Mat 1-12 + antigenic peptde 
  
Figure 31. ELISA competition experiments for Mat 1-12 (coating: 100ng of BDNF). The two 
graphs reports the competition curves of Mat  1-12 against the antigenic peptide (right panel) and 
recombinant BDNF (left panel). X axis represents the ng of soluble BDNF, Y axis represents the 
normalized percentage of coated BDNF bound by Mat 1-12. 100 ng of antigenic peptide 
demonstrated to be able to saturate almost completely Mat 1-12 with a satisfactory competition 
curve. The competition curve for Mat 1-12 + BDNF revealed to be not satisfactory, because the 
trend reached a plateau for 10 ng of soluble BDNF and a 50% saturation of Mat 1-12.   
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Future perspectives  
Once established that an ELISA test based on a competitive structure might be not 
suitable to our purposes, we designed a new platform based on ELISA sandwich. In this 
test, we planned to use as “detection” antibody for the dosage of total BDNF Mat 1-12, 
that demonstrated good affinity and specificity for this neurotrophin.   
Considering that pro total antibody reactivity was not entirely specific, it was necessary 
to produce a new “detection” antibody for the dosage of proBDNF. Therefore, in order 
to obtain a more specific detection antibody, we decided to start the production of a 
monoclonal antibody against the pro region.  
In addition, we planned the production of another monoclonal antibody also for the 
mature region. Thanks to this strategy, we will be able to utilize this monoclonal as the 
“capture” antibody for the kit (figure 32), ensuring a better binding specificity than a 
polyclonal immunoglobulin. Another advantage of the monoclonal antibodies is that 
they can be reproduced in a highly standardized manner, which is an essential feature for 
industrial projects.  
 
 
 
Figure 32. Schematic representation of the ELISA sandwich for the dosage of proBDNF/BDNF 
ratio. “Capture” antibodies is the monoclonal anti-BDNF, while the two “detection” antibodies 
are respectively Mat 1-12 and monoclonal anti-proBDNF.  
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Using Mat 1-12 and monoclonal anti proBDNF antibodies as “detection”, we will be 
able to estimate proBDNF/BDNF ratio in tested samples. To measure the amount of 
mature BDNF, it will be sufficient to subtract the amount of proBDNF detected with 
monoclonal anti-proBDNF to the BDNF total amount revealed by Mat 1-12, because 
Mat 1-12 recognizes both mature BDNF and proBDNF. 
At the moment, we are validating the recently produced monoclonal anti-BDNF and 
anti-proBDNF antibodies. 
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5. DISCUSSION 
 
 
5.1 Preliminary experiments 
Preliminary experiments were designed in order to identify novel biomarkers of 
cognitive processes that could constitute the scientific basement of clinical and industrial 
assays suitable for the screening of cognition enhancing properties of developing 
compounds. For this purpose, we focused our attention on Arc, an IEG involved in 
synaptic plasticity and long term memory formation. To assess the potential use of Arc 
as a marker of synaptic plasticity, this study utilised the M1 agonist xanomeline and the 
technique of quantitative in situ hybridisation to analyse Arc expression and its 
distribution in the brain of rats treated with the cognitive enhancer xanomeline, an 
agonist of M1 receptor.  
We decided to measure Arc mRNA expression and brain distribution following 
administration of xanomeline for many reasons. It is well established that the muscarinic 
cholinergic system is involved in cognitive processes and muscarinic M1 preferring 
agonists have been targeted for the treatment of cognitive deficits in disorders such as 
Alzheimer’s disease (AD) and have been demonstrated to improve cognition 
performances in animal models as well as in the clinic.  In particular, xanomeline has 
been shown to have pro cognitive effects in the 8 arm radial maze, an established animal 
model of spatial learning (Bymaster et al. 2002). Furthermore, recent data examining the 
effects of pilocarpine, an M1/M3 agonist, on the expression of the IEG Arc in the rat 
forebrain, suggests that a correlation exists between mAChR controlled signalling 
cascades, the induction of Arc and synaptic plasticity (Bymaster et al. 2002). Thus, 
administration of a compound capable to ameliorate cognitive performances, followed 
by the evaluation of Arc expression in brain areas specifically involved in cognitive 
processes (prefrontal cortex and hippocampus), allowed us to investigate Arc expression 
as a potential cognition biomarker.  
Results revealed a significant increase in Arc expression in the deep layers of the rat 
prefrontal cortex, 1 hour following xanomeline administration, at 3 and 10 mg/kg.  
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Significant changes in Arc expression were not detected in the superficial layers of the 
prefrontal cortex, or in any of the different areas of dorsal hippocampus studied (CA1, 
CA3 and DG). The increased Arc expression in the prefrontal cortex (deep layers) 
correlates with results from a parallel study using immunohistochemistry to examine the 
response of the IEG c-Fos to acute administration of xanomeline, where a robust 
increase in c-Fos expression in cortical areas (prefrontal cortex, somatosensory cortex, 
cingulate cortex) was observed (unpublished data).  
Although Arc expression was unchanged in the hippocampus, it should be noted that 
these animals were not habituated to handling and it is conceivable that hippocampal 
effects may have been obscured by stress. Indeed, the expression of IEGs is known to be 
affected by stress (Herrera et al. 1996) and in house studies have shown that handling 
and mock dosing for three days prior to the actual day of dosing may decrease basal 
levels of Arc (unpublished data).  
However, considering the controversial data about Arc expression in prefrontal cortex 
and hippocampus that did not ensure the use of Arc as a reliable biomarker of cognitive 
processes, we chose to abandon the study of this gene and test another biomarker of 
cognition.        
 
 
5.2 Cellular and molecular mechanisms of cognitive processes 
To individuate a new biomarker candidate of cognitive processes, we based our 
considerations on scientific literature and experimental evidence previously 
demonstrated in our laboratory. Consequently we reasoned that Brain-derived 
Neurotrophic Factor, due to its important role in neuroplasticity, could represent an 
interesting cognition biomarker. 
Indeed, BDNF mRNA upregulation is consistently involved in long-term synaptic 
plasticity, considering that its expression is enhanced by the LTP-inducing tetanic 
stimulation in CA1 (Patterson et al. 1992) and dentate gyrus (Castren et al. 1993; 
Dragunow et al. 1993). To support this linkage, numerous studies demonstrated that the 
tetanic stimulation-dependent BDNF transcription requires CREB, a cAMP-dependent 
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transcription factor which is strongly implicated in LTP and memory in different animal 
species (Shieh et al. 1998; Tao et al. 1998).  
Furthermore, BDFN expression revealed to be increased also in in vivo experiments with 
animal models. Radial arm maze training in rats for spatial learning and memory 
provokes a significant increase in the BDNF mRNA expression in the hippocampus 
(Mizuno et al. 2000; Mizuno et al. 2003). A rapid increase in BDNF mRNA expression 
has been noticed also in inhibitory avoidance training in dentate gyrus of the 
hippocampus (Ma et al. 1998; Alonso et al. 2002), and during hippocampus-dependent 
contextual learning (Hall et al. 2000). In addition, rats performance in Morris water 
maze and their exposure to enriched environment rapidly and selectively induce BDNF 
expression (Falkenberg et al. 1992). 
Previous experiments in our laboratory convinced us to study BDNF regulation for 
industrial and clinical applications. In fact, it was demonstrated in rats that 
administration of pilocarpine, which stimulate muscarinic acetylcholine receptor 
similarly to xanomeline, induces dendritic targeting of BDNF mRNA (Tongiorgi et al. 
2004). The dendritic targeting of BDNF mRNA, which is peculiar of some splice 
variants such as exon 2c and exon 6 (Chiaruttini et al. 2008), suggested us the idea of an 
extremely fine regulation of BDNF protein synthesis, where the dendritic mRNAs might 
be translated directly into dendrites to assure spatial and temporal specificity to synaptic 
plasticity. 
Before studying BDNF protein synthesis, a mechanism strongly involved in cognition 
(see Introduction, chapter 1.2), we investigated whether BDNF proteins, translated 
starting from the different mRNA splice variants, were localized in different neuronal 
compartments. We hypothesized that, if this happens, it is likely that dendritic BDNF 
proteins could be synthesized locally. Immunofluorescence experiments revealed that 
there is a differential distribution of BDNF proteins, and this distribution matches with 
the localization of BDNF mRNA slice variants (somatodendritic for exons 1 and 4, distal 
dendritic for exons 2c, 6 and CDS). Interestingly, other data from our laboratory 
(submitted article) showed that silencing of distal dendritic splice variants affects normal 
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dendritic arborisation and neuronal shaping, suggesting their involvement in synaptic 
plasticity. 
Based on this evidence, we overexpressed alternatively somatodendritic exon 4 or distal 
dendritic exon 6 to demonstrate BDNF local protein synthesis after electrical 
stimulation. Dendrites were mechanically separated from the soma to avoid protein 
transport, ensuring us the specificity of protein translation.  
Detection of protein translation in severed dendrites after KCl stimulation, estimated by 
fluorescence densitometry, represents the first unambiguous demonstration of BDNF 
local protein synthesis in dendrites. The increment revealed to be rapid reaching a peek 
at 15 minutes after stimulation, possibly indicating that LPS is important for a rapid 
delivery of BDNF to activated synapses but does not contribute to the immediate 
response (30 sec.- 3 min.) leading to BDNF secretion (Santi et al. 2006). Notably, this 
mechanism is peculiar of exon 6 and not of exon 4, supporting the idea of an 
involvement in synaptic plasticity of BDNF splice variants distributed along the distal 
dendrites. 
 Moreover, it is important to underline that the synthesis of new BDNF protein is 
particularly focused in “hot spots” that seem to be preferentially distributed along the 
apical dendrite of pyramidal neurons, in proximity of the branching points. This 
observation suggests the existence of translation sites along the dendrites that target new 
BDNF proteins to nearby synapses. Accordingly, it has been demonstrated that the 
dendritic distribution of Golgi-like apparatus (Golgi outposts), necessary for the post-
translational modifications of BDNF, is highly comparable with “hot spots” localization, 
supporting our observations (Horton et al. 2003). 
This set of experiments allowed us to better understand some fundamental aspects of 
BDNF regulation and to identify this neurotrophin as a potential biomarker of cognitive 
processes. In addition, the high fidelity of the method for LPS detection convinced us to 
plan an industrial assay for drug screening process, capable to individuate new 
compounds able to ameliorate cognitive functions in psychotics patients (see Results, 
chapter 4.2). The semi-automated measurement of LPS after neuronal stimulation with 
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developing drugs could represent a powerful tool for industrial drug screening process at 
the pre-clinical level.    
  
 
5.3 ProBDNF/BDNF ratio in the serum of schizophrenic patients 
After the individuation of BDNF as a biomarker of synaptic plasticity and the 
development of an industrial assay for drug screening, we investigated whether BDNF 
could be also utilized in clinical assays to evaluate neuropsychiatric disorders and 
associated cognitive deficit. Based on the scientific literature (see Introduction, chapter 
1.4), we focused our attention of BDNF protein levels in human serum, an accessible 
tissue sample.  
For this purpose, we collected serum samples from a population of healthy volunteers 
and from subjects affected by schizophrenia, the neuropsychiatric disorder with the 
highest incidence of cognitive deficit (Kurtz 2005). We selected our groups as much 
homogeneous as possible, avoiding possible BDNF variations due to age or sex reported 
in some studies (Lommatzsch et al. 2005). In addition, blood sampling was performed 
constantly in the early morning, to exclude influences due to hormonal or circadian 
changes. To investigate whether there is an alteration of BDNF levels due to 
pharmacological treatment, we collected serum from patients treated both with typical 
and atypical antipsychotic drugs.   
Considering the controversial results about total BDNF serum levels in schizophrenia 
(see Introduction, chapter 1.4), we firstly determined if there was a significant alteration 
in schizophrenia compared to BDNF serum levels in control group. For this and the 
following experiments, samples were processed within six months from the collection, 
eliminating the possibility of BDNF degradation due to long term storage or freeze-thaw 
cycles (Trajkovska et al. 2007). Using a commercially available ELISA kit, we did not 
find any variation of BDNF serum levels between schizophrenic and control groups.   
Nevertheless, considering the biological role played by proBDNF in modulating 
neuronal system, we decided to investigate whether there were alterations of the 
balancing between mature BDNF and its pro form.  
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Firstly, we demonstrated the existence of proBDNF in human serum using an antibody 
(anti-BDNF N-20, Santa Cruz) commonly used to detect pro and mature BDNF in other 
tissues or cell lysates (Marcinkiewicz et al. 1998; Michalski et al. 2003). Western blot 
detection revealed a predominant band correspondent to mature BDNF and a much 
lower signal for proBDNF. At best of our knowledge, this is the first demonstration of 
the presence of proBDNF at detectable levels in human serum. 
Subsequently, we selected 20 schizophrenic patients with diagnosed cognitive deficit 
and we measured their ratio proBDNF/BDNF by densitometry of the respective bands. It 
was decided to analyze the ratio instead of the single amounts of pro and mature BDNF 
for two reasons. At first, scientific literature suggests that neuronal modulation is 
influenced by the correct balancing of positive and negative signals determined by the 
two forms (Lu 2003). Therefore, estimation of a single BDNF form might not reflect the 
overall effects of BDNF modulation of neuronal circuits. In addition, the ratio 
proBDNF/BDNF is independent by the quantity of serum proteins loaded in the gel. 
From a technical point of view, even though we ensured to load the same amount of 
serum proteins for each sample with Bradford method, this measure allowed us to feel 
more confident about the data obtained.   
Comparison of serum proBDNF/BDNF ratio between schizophrenic subjects and 
healthy volunteers revealed a significant decrease in schizophrenic patients. These 
differences are unlikely to result from the difference in binding affinities of antibody N-
20 for proBDNF and mature BDNF as N-20 recognizes 20 amino acids at the N-
terminus of mature BDNF that are also present in proBDNF. 
Considering that mature BDNF is involved in neuronal survival and LTP, we would 
have expected an increment of proBDNF/BDNF ratio in schizophrenic patients, linked 
with apoptotic effects and LTD facilitation of proBDNF. However, some studies with 
magnetic resonance imaging (MRI) enlightened a volume increase in certain brain areas 
such as caudate, putamen and pallidum of the bilateral dorsal striatum of schizophrenic 
patients (Goldman et al. 2008), suggesting that the increase could be mediated by 
survival and proliferation effects due to endogenous signalling systems including those 
mediated by mature BDNF. In addition, studies in experimental models of epilepsy have 
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suggested that a large excess of mature BDNF could determine effects opposite to its 
normal positive modulation (Binder et al. 2001; Simonato et al. 2006). Indeed, increase 
in BDNF levels is considered to be strongly involved in hyperexcitable neuronal state 
typical of epilepsy, and in particular in animal models of epilepsy, it was observed a 
selective overexpression of mature BDNF while proBDNF remained at controls levels 
(Langone, personal communication). Hyperexcitability due to the excess of mature 
BDNF is determined by various different mechanisms, included enhanced glutamate-
mediated synaptic transmission and BDNF itself is known to potentiate glutamatergic 
transmission (Binder et al. 2001). Excessive release of glutamate was demonstrated to be 
associated with excitotoxicity, dendritotoxicity and spine loss (Swann et al. 2000; 
Henshall 2007). Considering these findings, it seems reasonable to hypothesize that an 
excess of positive modulation due to an overproduction of mature BDNF might be 
involved in cellular responses leading to a psychotic condition, such as for schizophrenic 
patients. Hence, treatments able to restore the normal balance of BDNF protein variants 
should be of benefit for these patients. 
From a molecular point of view, altered levels of proBDNF/BDNF ratio in psychotic 
subjects could be due to differences in the processing of proBDNF. Enhanced proteolitic 
cleavage of proBDNF, derived from enzymatic dysfunctions, may lead to a decrement of 
the ratio in the serum of schizophrenic patients. At the moment, there are no studies 
investigating possible alterations of proteolitic enzymes in schizophrenia. Nevertheless, 
it was demonstrated that mice lacking tissue plasminogen activator or plasminogen, 
members of the plasmin cascade leading to proteolitic processing of proBDNF, are 
protected by stress-induced reduction of dendritic spines and poor cognitive 
performances (Pawlak et al. 2005). These findings suggest that proBDNF is protective 
against stress-induced effects leading to depression-like disorders, correlating with 
decreased proBDNF/BDNF ratio in schizophrenic patients.  
Psychotic subjects were also tested for their cognitive performances with four different 
tests, to estimate cognitive functions such as attention, screening abilities, short term 
memory and working memory. These tests were chosen among others for their 
widespread employment in psychiatric field. A similar work was performed on parietal 
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cortex of Alzheimer patients, demonstrating a correlation between proBDFN levels and 
the severity of cognitive impairment (Peng et al. 2005).  
We were not able to identify any correlation between proBDNF/BDNF ratio and 
cognitive performances of schizophrenic subjects. However, it is possible that other test 
addressing different cognitive functions could reveal a correlation with the 
proBDNF/BDNF ratio.  
Finally, we found no significant differences in serum pro BDNF/BDNF ratio between 
patients treated with typical or atypical antipsychotic. This could be due to the small 
number of samples examined (8 typical and 12 atypical), considering that it seems to be 
noticed an increasing trend in subjects under typical antipsychotic treatment. In the next 
future, we intended to increase our sample population, screening the donors also with 
other neuropsychiatric tests, in order to understand if the ratio proBDNF/BDNF is 
correlated with cognitive performances and if it is influenced by antipsychotic treatment.            
    
 
5.4 Development of an ELISA kit for the dosage of proBDNF/BDNF ratio 
Our observations of a decrease in serum proBDNF/BDNF ratio of schizophrenic patients 
lead us to plan the development of a fast and reproducible Elisa assay for its 
quantification. The ELISA kit is predicted to be an important clinical support for the 
diagnosis of psychosis and possibly for the follow-up of antipsychotic treatment, as 
discussed in the previous chapter. At the moment, available commercial ELISA kits are 
capable to detect only the total amount of BDNF, without distinguish between pro and 
mature form.   
From the technical point of view, polyclonal antibody design was simple for what 
concern the identification of antigenic sites within BDNF mature region (3 antigenic 
sites found), whilst it was more problematic for proBDNF. We were able to identify a 
unique antigenic site, with excellent parameters of antigenicity and hydrophobicity, for 
the production of an antibody against the pro region. Similarly, proBDNF variants 
forced us to design the immunoglobulins on very small N-terminal fractions of the 
protein, avoiding any possibility of discrimination between different antigenic sites.  
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Once designed the immunogenic peptides, we decided to adopt a double strategy for the 
antibody generation characterized by the home made production or the externalization of 
the whole process. The strategy revealed to be successful, allowing us to obtain the 
entire set of antibodies validated in dot blot. 
Unfortunately, Western blot validation showed that antibodies against total proBDNF 
and the single proBDNF variants failed to recognize with specificity their targets in 
different cellular lysates. Pro total, the antibody against the pro region, revealed to have 
a weak immunoaffinity for proBDNF and an unexpected cross-reactivity with mature 
BDNF, both in cell lysates and in a preparation of the purified recombinant protein. 
Conversely, the antibodies against the proBDNF variants generally showed no reactivity. 
This could be due to the nature of the N-terminal region that they recognize. Pro1 and 
Pro2 are directed against sequences predicted to be part of a signal peptide by our 
analysis with SignalIP 3.0 software (Emanuelsson et al. 2007). Usually, signal peptides 
are cleaved immediately after protein translation, which would account for the lack of 
detection of these two proBDNF variants by the antibodies. Conversely, Pro3 was 
predicted to detect a sequence inside a signal anchor that inserts the nascent protein in 
the ER membrane without any cleavage of the peptide. This observation is confusing, 
because BDNF is a secreted protein sorted in vesicle and there are no evidences of its 
presence in the ER membrane. Moreover, if the signal anchor is not cleaved, pro3 
antibody should be able to detect pro3 protein variant, considering that it showed a 
satisfactory immunoreactivity in Dot blot experiments. Finally, pro4 might have failed to 
detect BDNF in Western blot because it is reported that the mRNA is expressed at very 
low levels in neurons (Liu et al. 2005), leading to the translation of a probably 
undetectable amount of protein. 
Our best antibody, Mat 1-12 against the mature region, was satisfactory validated in Dot 
blot, western blot and ELISA. Once established the necessity of an ELISA sandwich 
structure of the kit, which is the common format adopted by the commercial kits for the 
detection of total BDNF, we decided to utilize Mat 1-12 as the “detection” antibody for 
the measurement of mature BDNF. The other “detection” antibody for the pro form of 
BDNF is a monoclonal immunoglobulin that is currently under validation. Similarly, the 
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“capture” antibody needed for the immobilization of total BDNF will be another 
monoclonal antibody under validation. Monoclonal antibodies were produced to 
guarantee higher specificity and higher affinity of the binding than polyclonal 
immunoglobulins and a better reproducibility of the antibody production, which is 
essential for an industrial project. Measurement of proBDNF/BDNF ratio will be 
determined by a double detection of proBDNF and total BDNF in different wells. 
Mature BDNF will be deducted by subtraction of proBDNF signal from total BDNF 
amount. 
Prior the kit release on the market, we scheduled other clinical experiments. In 
particular, we are interested to understand if the ratio proBDNF/BDNF is altered in other 
neuropsychiatric disorders and if it is possible to individuate a strictly defined diagnostic 
range for clinical evaluation of psychotic subjects. Furthermore, we are interested to 
investigate if the ratio is altered after pharmacological treatment in the different 
neuropsychiatric disorders. If we were able to detect a variation, the kit might be 
extremely useful to support the follow-up of patients’ medical treatment, evaluating their 
response to antipsychotics. At the moment, we are collecting serum samples of patients 
with depression, bipolar disorder and Attention Deficit Hyperactivity Disorder for these 
studies.  
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6. CONCLUSIONS 
 
 
The PhD project philosophy was based upon the study of the basic cellular and 
molecular mechanisms of neuropsychiatric disorders and cognition, aimed to the 
development of industrial and clinical applications. Our approach was characterized by 
experiments performed both in vitro and in vivo, in order to achieve a better 
comprehension of the phenomena and to design industrial and clinical assays with the 
highest probability of success.  
Briefly, the aims of the thesis were: 
 
Aim 1) to study the cellular mechanisms of BDNF translation in dendrites; 
Industrial application: development of a cellular assay for the in vitro screening of 
compounds to treat cognitive deficit. 
Aim 2) to study the correlation between neuropsychiatric disorders, cognitive deficit and 
levels of BDNF in the serum. 
Clinical application: development of an ELISA kit for the dosage of BDNF in human 
serum as a biomarker of human cognitive deficits. 
 
Aim 1 allowed us to consistently identify BDNF as a biomarker of synaptic plasticity 
and cognitive processes. In particular, we gave the first demonstration of BDNF local 
protein synthesis in severed dendrites after electrical stimulation. The development of a 
cellular assay for the drug screening process, in which we utilize BDNF local protein 
synthesis as a biomarker of cognition enhancing properties of novel compounds, is the 
main core of a business plan for the start-up of a spin-off company. At the moment, we 
are validating the physical support for local protein synthesis detection. 
Aim 2, based on BDNF protein levels, was characterized by the demonstration of 
proBDNF existence in human serum. Especially, we demonstrated that, in schizophrenic 
subjects, there are no alterations in serum total BDNF compared to a control group, 
whilst there is a significant reduction of the proBDNF/BDNF ratio. 
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Considering this observation, we planned to develop an ELISA kit capable to estimate 
proBDNF/BDNF ratio for the diagnosis and for the follow-up of the medical treatment 
of patients affected by neuropsychatric disorders. The assay is different from the 
commercially available kits for BDNF detection, unable to discriminate between mature 
and pro form. At the moment, we are validating an ELISA “sandwich” platform. 
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